<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>FN3K - AI Gene Review</title>
    <style>
        :root {
            --color-accept: #22c55e;
            --color-remove: #ef4444;
            --color-modify: #f97316;
            --color-keep-non-core: #3b82f6;
            --color-undecided: #6b7280;
            --color-new: #8b5cf6;
            --color-mark-over: #eab308;
            --bg-light: #f9fafb;
            --border-color: #e5e7eb;
            --text-muted: #6b7280;
            --text-primary: #111827;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif;
            line-height: 1.6;
            color: var(--text-primary);
            background-color: #ffffff;
            padding: 2rem;
            max-width: 1400px;
            margin: 0 auto;
        }

        .header {
            border-bottom: 2px solid var(--border-color);
            padding-bottom: 1.5rem;
            margin-bottom: 2rem;
        }

        h1 {
            font-size: 2.5rem;
            font-weight: 700;
            margin-bottom: 0.5rem;
            color: #1f2937;
        }

        .gene-info {
            display: flex;
            gap: 2rem;
            flex-wrap: wrap;
            margin-top: 1rem;
        }

        .info-item {
            display: flex;
            gap: 0.5rem;
        }

        .info-label {
            font-weight: 600;
            color: var(--text-muted);
        }

        .aliases {
            display: flex;
            gap: 0.5rem;
            flex-wrap: wrap;
        }

        .badge {
            padding: 0.25rem 0.75rem;
            border-radius: 9999px;
            font-size: 0.875rem;
            font-weight: 500;
            background-color: var(--bg-light);
            border: 1px solid var(--border-color);
        }

        .status-badge {
            padding: 0.375rem 0.875rem;
            border-radius: 0.375rem;
            font-size: 0.875rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.025em;
        }

        .status-initialized {
            background-color: #fef3c7;
            color: #92400e;
            border: 1px solid #fde68a;
        }

        .status-in-progress {
            background-color: #dbeafe;
            color: #1e40af;
            border: 1px solid #bfdbfe;
        }

        .status-draft {
            background-color: #fce7f3;
            color: #831843;
            border: 1px solid #fbcfe8;
        }

        .status-complete {
            background-color: #d1fae5;
            color: #065f46;
            border: 1px solid #a7f3d0;
        }

        .description-card {
            background-color: var(--bg-light);
            border: 1px solid var(--border-color);
            border-radius: 0.5rem;
            padding: 1.5rem;
            margin-bottom: 2rem;
        }

        .description-card h2 {
            font-size: 1.25rem;
            margin-bottom: 1rem;
            color: #374151;
        }

        .section {
            margin-bottom: 2.5rem;
        }

        .section-title {
            font-size: 1.5rem;
            font-weight: 600;
            margin-bottom: 1.5rem;
            color: #1f2937;
            border-bottom: 1px solid var(--border-color);
            padding-bottom: 0.5rem;
        }

        .annotations-table {
            width: 100%;
            border-collapse: collapse;
            border: 1px solid var(--border-color);
            border-radius: 0.5rem;
            overflow: hidden;
        }

        .annotations-table thead {
            background-color: var(--bg-light);
        }

        .annotations-table th {
            text-align: left;
            padding: 1rem;
            font-weight: 600;
            border-bottom: 2px solid var(--border-color);
            font-size: 0.875rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
        }

        .annotations-table td {
            padding: 1rem;
            border-bottom: 1px solid var(--border-color);
        }

        .annotations-table tbody tr:hover {
            background-color: #f9fafb;
        }

        .action-badge {
            display: inline-block;
            padding: 0.375rem 0.75rem;
            border-radius: 0.375rem;
            font-size: 0.875rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.025em;
        }

        .action-accept {
            background-color: var(--color-accept);
            color: white;
        }

        .action-remove {
            background-color: var(--color-remove);
            color: white;
        }

        .action-modify {
            background-color: var(--color-modify);
            color: white;
        }

        .action-keep_as_non_core {
            background-color: var(--color-keep-non-core);
            color: white;
        }

        .action-undecided {
            background-color: var(--color-undecided);
            color: white;
        }

        .action-new {
            background-color: var(--color-new);
            color: white;
        }

        .action-mark_as_over_annotated {
            background-color: var(--color-mark-over);
            color: white;
        }

        .term-info {
            display: flex;
            flex-direction: column;
            gap: 0.25rem;
        }

        .term-id {
            font-family: monospace;
            font-size: 0.875rem;
            color: var(--text-muted);
        }

        .term-label {
            font-weight: 500;
        }

        .evidence-code {
            font-family: monospace;
            background-color: var(--bg-light);
            padding: 0.125rem 0.375rem;
            border-radius: 0.25rem;
            font-size: 0.875rem;
        }

        .core-function-card {
            background-color: white;
            border: 1px solid var(--border-color);
            border-radius: 0.5rem;
            padding: 1.5rem;
            margin-bottom: 1rem;
        }

        .core-function-card h3 {
            font-size: 1.125rem;
            margin-bottom: 1rem;
            color: #1f2937;
        }

        .core-function-statement {
            margin-bottom: 1rem;
            padding: 0.75rem;
            background-color: var(--bg-light);
            border-left: 4px solid var(--color-accept);
            border-radius: 0.25rem;
        }

        .function-annotations {
            display: flex;
            flex-wrap: wrap;
            gap: 0.5rem;
            margin-top: 1rem;
        }

        .reference-item {
            border: 1px solid var(--border-color);
            border-radius: 0.5rem;
            padding: 1rem;
            margin-bottom: 1rem;
        }

        .reference-header {
            display: flex;
            justify-content: space-between;
            align-items: start;
            margin-bottom: 0.75rem;
        }

        .reference-id {
            font-family: monospace;
            font-weight: 600;
            color: #2563eb;
        }

        .supported-by {
            margin-top: 0.5rem;
            padding: 0.5rem;
            background-color: #f3f4f6;
            border-left: 3px solid #3b82f6;
            border-radius: 0.25rem;
            font-size: 0.875rem;
        }

        .supported-by-title {
            font-weight: 600;
            color: #4b5563;
            margin-bottom: 0.25rem;
        }

        .support-item {
            margin-bottom: 0.5rem;
        }

        .support-ref {
            font-weight: 500;
            color: #2563eb;
        }

        .support-text {
            color: #6b7280;
            font-style: italic;
            margin-left: 1rem;
        }

        a.term-link {
            color: #2563eb;
            text-decoration: none;
        }

        a.term-link:hover {
            text-decoration: underline;
        }

        .core-function-terms {
            margin-top: 1rem;
        }

        .function-term-group {
            margin-bottom: 1rem;
        }

        .function-term-label {
            font-weight: 600;
            color: #4b5563;
            margin-bottom: 0.25rem;
        }

        .reference-title {
            font-weight: 500;
            margin-bottom: 0.5rem;
        }

        .findings-list {
            margin-top: 1rem;
            padding-left: 1.5rem;
        }

        .finding-item {
            margin-bottom: 0.75rem;
        }

        .finding-statement {
            font-weight: 500;
            margin-bottom: 0.25rem;
        }

        .finding-text {
            color: var(--text-muted);
            font-size: 0.95rem;
            font-style: italic;
        }

        .proposed-term {
            border: 1px solid var(--border-color);
            border-radius: 0.5rem;
            padding: 1rem;
            margin-bottom: 1rem;
            background-color: #fef3c7;
        }

        .question-card {
            border: 1px solid var(--border-color);
            border-radius: 0.5rem;
            padding: 1rem;
            margin-bottom: 1rem;
            background-color: #dbeafe;
        }

        .experiment-card {
            border: 1px solid var(--border-color);
            border-radius: 0.5rem;
            padding: 1rem;
            margin-bottom: 1rem;
            background-color: #f3e8ff;
        }

        .collapsible {
            cursor: pointer;
            user-select: none;
        }

        .collapsible:after {
            content: ' ‚ñº';
            font-size: 0.75rem;
        }

        .collapsible.collapsed:after {
            content: ' ‚ñ∫';
        }

        .collapse-content {
            transition: max-height 0.3s ease;
            overflow: hidden;
        }

        .collapsed + .collapse-content {
            max-height: 0;
        }

        .no-data {
            color: var(--text-muted);
            font-style: italic;
            padding: 1rem;
            text-align: center;
            background-color: var(--bg-light);
            border-radius: 0.5rem;
        }

        /* Styling for markdown section summaries with voting */
        .markdown-section summary {
            padding: 0.75rem;
            background: var(--bg-light);
            border-radius: 0.5rem;
            margin-bottom: 0.5rem;
        }

        .markdown-section summary:hover {
            background: #e5e7eb;
        }

        .markdown-section summary .vote-buttons {
            margin-left: auto;
        }

        @media print {
            body {
                padding: 1rem;
            }

            .collapsible:after {
                display: none;
            }

            .collapsed + .collapse-content {
                max-height: none !important;
            }
        }

        @media (max-width: 768px) {
            body {
                padding: 1rem;
            }

            h1 {
                font-size: 2rem;
            }

            .annotations-table {
                font-size: 0.875rem;
            }

            .annotations-table th,
            .annotations-table td {
                padding: 0.5rem;
            }
        }
    </style>
</head>
<body>
    <div class="header">
        <h1>FN3K</h1>
        <div class="gene-info">
            
            <div class="info-item">
                
                <span class="info-label">UniProt ID:</span>
                <span>
                    <a href="https://www.uniprot.org/uniprotkb/Q9H479" target="_blank" class="term-link">
                        Q9H479
                    </a>
                </span>
                
            </div>
            
            
            <div class="info-item">
                <span class="info-label">Organism:</span>
                <span>Homo sapiens</span>
            </div>
            
            
            <div class="info-item">
                <span class="info-label">Review Status:</span>
                <span class="status-badge status-draft">
                    DRAFT
                </span>
            </div>
            
            
        </div>
        <div style="margin-top: 1rem; text-align: center;">
            <a id="feedback-form-link"
               href="#"
               target="_blank"
               style="display: inline-block; padding: 10px 20px; background-color: #4CAF50; color: white; text-decoration: none; border-radius: 5px; font-weight: 600;">
                üìù Provide Detailed Feedback
            </a>
            <script>
                // Construct the form URL with proper encoding
                // Extract organism code from the current page path (e.g., /genes/ARATH/APO1/ -> ARATH)
                const pathParts = window.location.pathname.split('/');
                const genesIndex = pathParts.indexOf('genes');
                let organism = '';
                if (genesIndex !== -1 && pathParts[genesIndex + 1]) {
                    organism = pathParts[genesIndex + 1].toUpperCase();
                }
                const geneSymbol = "FN3K";
                const speciesGene = organism + ' ' + geneSymbol;
                const formBaseUrl = 'https://docs.google.com/forms/d/e/1FAIpQLSdTot9L6GVkkZYgLQT0E8ZdAJv8RiN5ZgOVkgWNcKSbYvxxzQ/viewform';
                const entryId = '1226477767'; // Correct entry ID for Species/Gene field
                const formUrl = formBaseUrl + '?entry.' + entryId + '=' + encodeURIComponent(speciesGene);
                const feedbackLink = document.getElementById('feedback-form-link');
                feedbackLink.href = formUrl;
                // Add tooltip showing the pre-filled value
                feedbackLink.title = 'Opens form with pre-filled: ' + speciesGene;
            </script>
        </div>
    </div>

    
    <div class="description-card">
        <div style="display: flex; justify-content: space-between; align-items: center;">
            <h2>Gene Description</h2>
            <span class="vote-buttons" data-g="Q9H479" data-a="DESCRIPTION: Fructosamine-3-kinase (FN3K) is a protein repair e..." data-r="" data-act="DESCRIPTION">
                <button class="vote-btn" data-v="up" title="Agree with this description">üëç</button>
                <button class="vote-btn" data-v="down" title="Disagree with this description">üëé</button>
            </span>
        </div>
        <p>Fructosamine-3-kinase (FN3K) is a protein repair enzyme that catalyzes the ATP-dependent phosphorylation of fructosamines (Amadori products) on glycated proteins at the 3-position of the sugar moiety. This phosphorylation creates an unstable intermediate (fructosamine 3-phosphate) that spontaneously decomposes to release 3-deoxyglucosone, inorganic phosphate, and the regenerated free lysine residue, thereby reversing non-enzymatic glycation. FN3K is widely expressed but particularly active in erythrocytes where it participates in hemoglobin deglycation. The enzyme can also phosphorylate psicosamines and ribulosamines with lower efficiency. FN3K activity is redox-regulated through a P-loop cysteine residue.</p>
    </div>
    

    

    
    <div class="section">
        <h2 class="section-title">Existing Annotations Review</h2>
        <table class="annotations-table">
            <thead>
                <tr>
                    <th>GO Term</th>
                    <th>Evidence</th>
                    <th>Action</th>
                    <th>Reason</th>
                </tr>
            </thead>
            <tbody>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0016301" target="_blank" class="term-link">
                                    GO:0016301
                                </a>
                            </span>
                            <span class="term-label">kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IBA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000033
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-keepasnoncore">
                            KEEP AS NON CORE
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0016301" data-r="GO_REF:0000033" data-act="KEEP_AS_NON_CORE">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Correct but too general. FN3K has specific fructosamine 3-kinase activity (GO:0102194) which is more informative. The generic kinase activity annotation is redundant given that more specific MF annotations exist.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0030389" target="_blank" class="term-link">
                                    GO:0030389
                                </a>
                            </span>
                            <span class="term-label">fructosamine metabolic process</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IBA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000033
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0030389" data-r="GO_REF:0000033" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Appropriate BP annotation. FN3K is involved in fructosamine metabolism by phosphorylating fructosamines to initiate their removal from proteins. This is a core function.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0000166" target="_blank" class="term-link">
                                    GO:0000166
                                </a>
                            </span>
                            <span class="term-label">nucleotide binding</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IEA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000043
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-modify">
                            MODIFY
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0000166" data-r="GO_REF:0000043" data-act="MODIFY">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Redundant with more specific ATP binding annotation (GO:0005524). Should be removed in favor of the more specific term.
                        </div>
                        
                        
                        
                        <div style="margin-top: 0.5rem;">
                            <strong>Proposed replacements:</strong>
                            
                            <span class="badge">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0005524" target="_blank" class="term-link">
                                    ATP binding
                                </a>
                            </span>
                            
                        </div>
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0005524" target="_blank" class="term-link">
                                    GO:0005524
                                </a>
                            </span>
                            <span class="term-label">ATP binding</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IEA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000043
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0005524" data-r="GO_REF:0000043" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Correct. FN3K uses ATP as phosphate donor for its kinase activity. Kinetic data confirms ATP binding. UniProt documents ATP binding site at residues 89-91.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0016301" target="_blank" class="term-link">
                                    GO:0016301
                                </a>
                            </span>
                            <span class="term-label">kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IEA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000043
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-keepasnoncore">
                            KEEP AS NON CORE
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0016301" data-r="GO_REF:0000043" data-act="KEEP_AS_NON_CORE">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Duplicate of IBA annotation to same term. Correct but too general - the specific protein-fructosamine 3-kinase activity (GO:0102194) should be preferred.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0016740" target="_blank" class="term-link">
                                    GO:0016740
                                </a>
                            </span>
                            <span class="term-label">transferase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IEA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000043
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-remove">
                            REMOVE
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0016740" data-r="GO_REF:0000043" data-act="REMOVE">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Too general. This is a high-level parent term of kinase activity. Not informative when more specific annotations exist.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0102193" target="_blank" class="term-link">
                                    GO:0102193
                                </a>
                            </span>
                            <span class="term-label">protein-ribulosamine 3-kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IEA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000120
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-keepasnoncore">
                            KEEP AS NON CORE
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0102193" data-r="GO_REF:0000120" data-act="KEEP_AS_NON_CORE">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> FN3K can phosphorylate ribulosamines (PMID:14633848) but with lower affinity than fructosamines. The KM for deoxymorpholinoribulose is 2.6 uM vs 10 uM for DMF. However, the primary physiological substrate is fructosamines from glucose glycation. FN3KRP is the dedicated ribulosamine kinase. This annotation is technically correct but represents a secondary activity.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0102194" target="_blank" class="term-link">
                                    GO:0102194
                                </a>
                            </span>
                            <span class="term-label">protein-fructosamine 3-kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IEA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000120
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0102194" data-r="GO_REF:0000120" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Core molecular function. FN3K specifically phosphorylates fructoselysine residues on glycated proteins at the 3-position, generating fructosamine 3-phosphate. This is the defining enzymatic activity of FN3K (EC 2.7.1.171).
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0005829" target="_blank" class="term-link">
                                    GO:0005829
                                </a>
                            </span>
                            <span class="term-label">cytosol</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IEA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000120
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0005829" data-r="GO_REF:0000120" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Correct. FN3K is present in the cytosol where it can act on cytoplasmic glycated proteins. Evidence from multiple studies supports cytosolic localization.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0043687" target="_blank" class="term-link">
                                    GO:0043687
                                </a>
                            </span>
                            <span class="term-label">post-translational protein modification</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">TAS</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            Reactome:R-HSA-163841
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-markasoverannotated">
                            MARK AS OVER ANNOTATED
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0043687" data-r="Reactome:R-HSA-163841" data-act="MARK_AS_OVER_ANNOTATED">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Questionable pathway assignment. R-HSA-163841 covers gamma carboxylation, hypusinylation, hydroxylation - irreversible PTMs. FN3K is involved in REMOVING glycation (deglycation), not adding PTMs. The phosphorylation FN3K performs on glycated substrates is transient and part of a repair process, not a stable modification. This annotation may be misleading about FN3K&#39;s actual function.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0005739" target="_blank" class="term-link">
                                    GO:0005739
                                </a>
                            </span>
                            <span class="term-label">mitochondrion</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IDA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            GO_REF:0000052
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0005739" data-r="GO_REF:0000052" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Supported by IDA evidence (HPA immunofluorescence data). Multi-omics studies also confirm mitochondrial localization and interaction with mitochondrial proteins. FN3K may deglycate mitochondrial proteins.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0016301" target="_blank" class="term-link">
                                    GO:0016301
                                </a>
                            </span>
                            <span class="term-label">kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">TAS</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            Reactome:R-HSA-6788867
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-keepasnoncore">
                            KEEP AS NON CORE
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0016301" data-r="Reactome:R-HSA-6788867" data-act="KEEP_AS_NON_CORE">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Third annotation to the same generic term. Correct but too general - the specific protein-fructosamine 3-kinase activity (GO:0102194) should be preferred. Keeping consistent with other kinase activity annotations.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0036525" target="_blank" class="term-link">
                                    GO:0036525
                                </a>
                            </span>
                            <span class="term-label">protein deglycation</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IDA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11522682" target="_blank" class="term-link" style="font-size: 0.75rem;">
                                PMID:11522682
                            </a>
                            
                                
                                
                                <br>
                                <span style="font-size: 0.7rem; color: #666; font-style: italic;">
                                    Human fructosamine-3-kinase: purification, sequencing, subst...
                                </span>
                                
                            
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0036525" data-r="PMID:11522682" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Core biological process. PMID:11522682 (Szwergold et al.) directly demonstrated that FN3K phosphorylation of fructoselysine destabilizes the adduct, leading to spontaneous decomposition and reversal of glycation. This is the primary biological function of FN3K.
                        </div>
                        
                        
                        
                        
                        <div class="supported-by">
                            <div class="supported-by-title">Supporting Evidence:</div>
                            
                            <div class="support-item">
                                <span class="support-ref">
                                    
                                    file:human/FN3K/FN3K-deep-research-perplexity.md
                                    
                                </span>
                                
                                <div class="support-text">FN3K&#39;s enzymatic phosphorylation at the C3 position creates an unstable fructosamine-3-phosphate intermediate that spontaneously decomposes</div>
                                
                            </div>
                            
                        </div>
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0036525" target="_blank" class="term-link">
                                    GO:0036525
                                </a>
                            </span>
                            <span class="term-label">protein deglycation</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IDA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11975663" target="_blank" class="term-link" style="font-size: 0.75rem;">
                                PMID:11975663
                            </a>
                            
                                
                                
                                <br>
                                <span style="font-size: 0.7rem; color: #666; font-style: italic;">
                                    Fructosamine 3-kinase is involved in an intracellular deglyc...
                                </span>
                                
                            
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0036525" data-r="PMID:11975663" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Same term as above with additional supporting evidence. PMID:11975663 (Delpierre et al.) provided in vivo evidence in erythrocytes showing FN3K mediates intracellular deglycation of hemoglobin. DMF inhibitor experiments proved FN3K involvement in removing fructosamine residues. Strong supporting evidence for this core function.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0102194" target="_blank" class="term-link">
                                    GO:0102194
                                </a>
                            </span>
                            <span class="term-label">protein-fructosamine 3-kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IDA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11016445" target="_blank" class="term-link" style="font-size: 0.75rem;">
                                PMID:11016445
                            </a>
                            
                                
                                
                                <br>
                                <span style="font-size: 0.7rem; color: #666; font-style: italic;">
                                    Identification, cloning, and heterologous expression of a ma...
                                </span>
                                
                            
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0102194" data-r="PMID:11016445" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Core molecular function with strong experimental evidence. The discovery paper demonstrated FN3K phosphorylates fructosamines at the third carbon position via NMR analysis of products. Substrates tested included DMF, fructoselysine, fructoseglycine, and glycated lysozyme.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0102194" target="_blank" class="term-link">
                                    GO:0102194
                                </a>
                            </span>
                            <span class="term-label">protein-fructosamine 3-kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IDA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11522682" target="_blank" class="term-link" style="font-size: 0.75rem;">
                                PMID:11522682
                            </a>
                            
                                
                                
                                <br>
                                <span style="font-size: 0.7rem; color: #666; font-style: italic;">
                                    Human fructosamine-3-kinase: purification, sequencing, subst...
                                </span>
                                
                            
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0102194" data-r="PMID:11522682" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Duplicate annotation to same term with additional supporting evidence. PMID:11522682 confirmed substrate specificity and characterized the enzyme. Supports core MF.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0102194" target="_blank" class="term-link">
                                    GO:0102194
                                </a>
                            </span>
                            <span class="term-label">protein-fructosamine 3-kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IDA</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11975663" target="_blank" class="term-link" style="font-size: 0.75rem;">
                                PMID:11975663
                            </a>
                            
                                
                                
                                <br>
                                <span style="font-size: 0.7rem; color: #666; font-style: italic;">
                                    Fructosamine 3-kinase is involved in an intracellular deglyc...
                                </span>
                                
                            
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0102194" data-r="PMID:11975663" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Third IDA annotation to same term. Evidence from in vivo erythrocyte studies confirming FN3K activity on hemoglobin fructosamines.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0005829" target="_blank" class="term-link">
                                    GO:0005829
                                </a>
                            </span>
                            <span class="term-label">cytosol</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">TAS</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            Reactome:R-HSA-6788867
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0005829" data-r="Reactome:R-HSA-6788867" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Duplicate cytosol annotation from Reactome pathway. Consistent with other evidence supporting cytosolic localization.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0030855" target="_blank" class="term-link">
                                    GO:0030855
                                </a>
                            </span>
                            <span class="term-label">epithelial cell differentiation</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">IEP</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/21492153" target="_blank" class="term-link" style="font-size: 0.75rem;">
                                PMID:21492153
                            </a>
                            
                                
                                
                                <br>
                                <span style="font-size: 0.7rem; color: #666; font-style: italic;">
                                    Analysis of proteomic changes induced upon cellular differen...
                                </span>
                                
                            
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-remove">
                            REMOVE
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0030855" data-r="PMID:21492153" data-act="REMOVE">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Weak evidence. PMID:21492153 is a proteomics study of Caco-2 cell differentiation where FN3K was identified as one of 34 differentially expressed proteins. This shows expression correlation, not functional involvement in differentiation. FN3K&#39;s deglycation activity has no mechanistic connection to epithelial differentiation. This appears to be an over-interpretation of high-throughput expression data.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0030393" target="_blank" class="term-link">
                                    GO:0030393
                                </a>
                            </span>
                            <span class="term-label">fructoselysine metabolic process</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">NAS</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11016445" target="_blank" class="term-link" style="font-size: 0.75rem;">
                                PMID:11016445
                            </a>
                            
                                
                                
                                <br>
                                <span style="font-size: 0.7rem; color: #666; font-style: italic;">
                                    Identification, cloning, and heterologous expression of a ma...
                                </span>
                                
                            
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0030393" data-r="PMID:11016445" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Appropriate annotation. FN3K phosphorylates fructoselysine (protein-bound and free) as a primary substrate. The discovery paper demonstrated high affinity for fructoselysine. This is more specific than GO:0030389 (fructosamine metabolic process).
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
                <tr>
                    <td>
                        <div class="term-info">
                            
                            <span class="term-id">
                                <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0102194" target="_blank" class="term-link">
                                    GO:0102194
                                </a>
                            </span>
                            <span class="term-label">protein-fructosamine 3-kinase activity</span>
                            
                        </div>
                    </td>
                    <td>
                        <span class="evidence-code">NAS</span>
                        
                        <br>
                        <span style="font-size: 0.75rem;">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11016445" target="_blank" class="term-link" style="font-size: 0.75rem;">
                                PMID:11016445
                            </a>
                            
                                
                                
                                <br>
                                <span style="font-size: 0.7rem; color: #666; font-style: italic;">
                                    Identification, cloning, and heterologous expression of a ma...
                                </span>
                                
                            
                            
                        </span>
                        
                    </td>
                    <td>
                        <span class="action-badge action-accept">
                            ACCEPT
                        </span>
                        <span class="vote-buttons" data-g="Q9H479" data-a="GO:0102194" data-r="PMID:11016445" data-act="ACCEPT">
                            <button class="vote-btn" data-v="up" title="Agree with this decision">üëç</button>
                            <button class="vote-btn" data-v="down" title="Disagree with this decision">üëé</button>
                        </span>
                    </td>
                    <td>
                        
                        <div style="margin-bottom: 0.5rem;">
                            <strong>Summary:</strong> Another annotation to the core MF term with NAS evidence. Redundant with IDA annotations but consistent.
                        </div>
                        
                        
                        
                        
                    </td>
                </tr>
                
            </tbody>
        </table>
    </div>
    

    
    <div class="section">
        <h2 class="section-title">Core Functions</h2>
        
        <div class="core-function-card">
            
            <div style="display: flex; justify-content: space-between; align-items: center;">
                <h3>Catalyzes ATP-dependent phosphorylation of fructoselysine residues on glycated proteins at the 3-position of the fructose moiety, generating fructosamine 3-phosphate as an unstable intermediate.</h3>
                <span class="vote-buttons" data-g="Q9H479" data-a="FUNCTION: Catalyzes ATP-dependent phosphorylation of fructos..." data-r="" data-act="CORE_FUNCTION">
                    <button class="vote-btn" data-v="up" title="Agree with this core function">üëç</button>
                    <button class="vote-btn" data-v="down" title="Disagree with this core function">üëé</button>
                </span>
            </div>
            

            <div class="core-function-terms">
                
                <div class="function-term-group">
                    <div class="function-term-label">Molecular Function:</div>
                    <span class="badge">
                        <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0102194" target="_blank" class="term-link">
                            protein-fructosamine 3-kinase activity
                        </a>
                    </span>
                </div>
                

                
                <div class="function-term-group">
                    <div class="function-term-label">Directly Involved In:</div>
                    <div class="function-annotations">
                        
                        <span class="badge">
                            <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0036525" target="_blank" class="term-link">
                                protein deglycation
                            </a>
                        </span>
                        
                    </div>
                </div>
                

                
                <div class="function-term-group">
                    <div class="function-term-label">Cellular Locations:</div>
                    <div class="function-annotations">
                        
                        <span class="badge">
                            <a href="https://www.ebi.ac.uk/QuickGO/term/GO:0005829" target="_blank" class="term-link">
                                cytosol
                            </a>
                        </span>
                        
                    </div>
                </div>
                

                

                
                <div class="function-term-group">
                    <div class="function-term-label">Substrates:</div>
                    <div class="function-annotations">
                        
                        <span class="badge">
                            <a href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:24103" target="_blank" class="term-link">
                                fructosamine
                            </a>
                        </span>
                        
                        <span class="badge">
                            <a href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:87177" target="_blank" class="term-link">
                                ribulosamine
                            </a>
                        </span>
                        
                        <span class="badge">
                            <a href="https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:87176" target="_blank" class="term-link">
                                psicosamine
                            </a>
                        </span>
                        
                    </div>
                </div>
                
            </div>

            
            <div style="margin-top: 1rem; padding-top: 1rem; border-top: 1px solid var(--border-color);">
                <strong>Supporting Evidence:</strong>
                <ul class="findings-list">
                    
                    <li class="finding-item">
                        <span class="reference-id">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11016445" target="_blank" class="term-link">
                                PMID:11016445
                            </a>
                            
                        </span>
                        
                        <div class="finding-text">Nuclear magnetic resonance analysis of phosphorylated DMF and phosphorylated fructoseglycine showed that the phosphate was bound to the third carbon of the 1-deoxyfructose moiety.</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <span class="reference-id">
                            
                            <a href="https://pubmed.ncbi.nlm.nih.gov/11522682" target="_blank" class="term-link">
                                PMID:11522682
                            </a>
                            
                        </span>
                        
                        <div class="finding-text">This phosphorylation destabilizes the FL adduct and leads to its spontaneous decomposition, thereby reversing the nonenzymatic glycation process at an early stage.</div>
                        
                    </li>
                    
                </ul>
            </div>
            
        </div>
        
    </div>
    

    
    <div class="section">
        <h2 class="section-title collapsible">References</h2>
        <div class="collapse-content">
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        <a href="https://github.com/geneontology/go-site/blob/master/metadata/gorefs/goref-0000033.md" target="_blank" class="term-link">
                            GO_REF:0000033
                        </a>
                        
                    </span>
                </div>
                
                <div class="reference-title">Annotation inferences using phylogenetic trees</div>
                
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        <a href="https://github.com/geneontology/go-site/blob/master/metadata/gorefs/goref-0000043.md" target="_blank" class="term-link">
                            GO_REF:0000043
                        </a>
                        
                    </span>
                </div>
                
                <div class="reference-title">Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping</div>
                
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        <a href="https://github.com/geneontology/go-site/blob/master/metadata/gorefs/goref-0000052.md" target="_blank" class="term-link">
                            GO_REF:0000052
                        </a>
                        
                    </span>
                </div>
                
                <div class="reference-title">Gene Ontology annotation based on curation of immunofluorescence data</div>
                
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        <a href="https://github.com/geneontology/go-site/blob/master/metadata/gorefs/goref-0000120.md" target="_blank" class="term-link">
                            GO_REF:0000120
                        </a>
                        
                    </span>
                </div>
                
                <div class="reference-title">Combined Automated Annotation using Multiple IEA Methods</div>
                
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        Reactome:R-HSA-163841
                        
                    </span>
                </div>
                
                <div class="reference-title">Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation</div>
                
                
                <ul class="findings-list">
                    
                    <li class="finding-item">
                        <div class="finding-statement">This pathway covers irreversible post-translational modifications including gamma-carboxylation, hypusinylation, and hydroxylation - FN3K&#39;s deglycation activity does not fit this category of irreversible modifications.</div>
                        
                        <div class="finding-text">"After translation, many newly formed proteins undergo further covalent modifications that alter their functional properties and that are essentially irreversible under physiological conditions in the body. These modifications include the vitamin K-dependent attachment of carboxyl groups to glutamate residues and the conversion of a lysine residue in eIF5A to hypusine"</div>
                        
                    </li>
                    
                </ul>
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        Reactome:R-HSA-6788867
                        
                    </span>
                </div>
                
                <div class="reference-title">FN3K phosphorylates ketosamines</div>
                
                
                <ul class="findings-list">
                    
                    <li class="finding-item">
                        <div class="finding-statement">FN3K phosphorylates ketosamines on the third carbon of the sugar moiety, creating unstable intermediates that decompose (deglycation).</div>
                        
                        <div class="finding-text">"Ketosamine-3-kinase (FN3K) and ketosamine-3-kinase-related protein (FN3KRP) can phosphorylate protein-bound or free ketosamines on the third carbon of the sugar moiety and the resultant, unstable ketosamine 3-phosphates decompose under physiological conditions (a process called deglycation)."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">FN3K and FN3KRP both phosphorylate psicosamines and ribulosamines, but only FN3K can phosphorylate fructosamines.</div>
                        
                        <div class="finding-text">"Both enzymes can 3-phosphorylate psicosamines (PsiAm) and ribulosamines (RibAm), but only FN3K can 3-phosphorylate fructosamines (FruAm) as well"</div>
                        
                    </li>
                    
                </ul>
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        <a href="https://pubmed.ncbi.nlm.nih.gov/11016445" target="_blank" class="term-link">
                            PMID:11016445
                        </a>
                        
                    </span>
                </div>
                
                <div class="reference-title">Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase.</div>
                
                
                <ul class="findings-list">
                    
                    <li class="finding-item">
                        <div class="finding-statement">Discovery paper identifying and cloning FN3K from erythrocytes, purified as 35,000 Mr protein.</div>
                        
                        <div class="finding-text">"The enzyme responsible for this conversion was purified approximately 2,500-fold by chromatography on Blue Sepharose, Q Sepharose, and Sephacryl S-200 and shown to copurify with a 35,000-M(r) protein."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Enzyme phosphorylates DMF, fructoselysine, fructoseglycine, and fructose in order of decreasing affinity.</div>
                        
                        <div class="finding-text">"They were shown to catalyze the phosphorylation of DMF, fructoselysine, fructoseglycine, and fructose in order of decreasing affinity."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">NMR analysis showed phosphate bound to third carbon of 1-deoxyfructose moiety.</div>
                        
                        <div class="finding-text">"Nuclear magnetic resonance analysis of phosphorylated DMF and phosphorylated fructoseglycine showed that the phosphate was bound to the third carbon of the 1-deoxyfructose moiety."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Phosphorylated glycated lysozyme but not unmodified lysozyme.</div>
                        
                        <div class="finding-text">"They also phosphorylated glycated lysozyme, though not unmodified lysozyme."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Proposed function is to initiate deglycation of fructoselysine and glycated proteins.</div>
                        
                        <div class="finding-text">"The physiological function of fructosamine-3-kinase may be to initiate a process leading to the deglycation of fructoselysine and of glycated proteins."</div>
                        
                    </li>
                    
                </ul>
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        <a href="https://pubmed.ncbi.nlm.nih.gov/11522682" target="_blank" class="term-link">
                            PMID:11522682
                        </a>
                        
                    </span>
                </div>
                
                <div class="reference-title">Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo.</div>
                
                
                <ul class="findings-list">
                    
                    <li class="finding-item">
                        <div class="finding-statement">Characterized human FN3K as a 35-kDa monomer expressed in all mammalian tissues.</div>
                        
                        <div class="finding-text">"The protein thus identified is a 35-kDa monomer that appears to be expressed in all mammalian tissues."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">FL3P phosphorylation destabilizes FL adduct and leads to spontaneous decomposition, reversing nonenzymatic glycation.</div>
                        
                        <div class="finding-text">"This phosphorylation destabilizes the FL adduct and leads to its spontaneous decomposition, thereby reversing the nonenzymatic glycation process at an early stage."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">High affinity of FN3K for FL and wide distribution suggest function is deglycation of nonenzymatically glycated proteins.</div>
                        
                        <div class="finding-text">"The lability of FL3P, the high affinity of FN3K for FL, and the wide distribution of FN3K suggest that the function of this enzyme is deglycation of nonenzymatically glycated proteins."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Deglycation system mediated by FN3K may protect cells from deleterious effects of nonenzymatic glycation.</div>
                        
                        <div class="finding-text">"a deglycation system mediated by FN3K may be an important factor in protecting cells from the deleterious effects of nonenzymatic glycation."</div>
                        
                    </li>
                    
                </ul>
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        <a href="https://pubmed.ncbi.nlm.nih.gov/11975663" target="_blank" class="term-link">
                            PMID:11975663
                        </a>
                        
                    </span>
                </div>
                
                <div class="reference-title">Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes.</div>
                
                
                <ul class="findings-list">
                    
                    <li class="finding-item">
                        <div class="finding-statement">In vivo evidence of FN3K activity in erythrocytes with formation of phosphorylated hemoglobin intermediate.</div>
                        
                        <div class="finding-text">"incubation of human erythrocytes with 200 mM glucose not only caused the progressive formation of glycated haemoglobin, but also increased the level of an anionic form of haemoglobin containing alkali-labile phosphate, to approx. 5% of total haemoglobin."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">DMF (FN3K inhibitor) doubled accumulation of glycated hemoglobin but decreased phosphorylated form - proving FN3K involvement.</div>
                        
                        <div class="finding-text">"1-Deoxy-1-morpholinofructose (DMF), a substrate and competitive inhibitor of fructosamine 3-kinase, doubled the rate of accumulation of glycated haemoglobin, but markedly decreased the amount of haemoglobin containing alkali-labile phosphate."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Removal of DMF caused decrease in glycated hemoglobin and transient increase in FN3P-Hb, demonstrating active deglycation cycle.</div>
                        
                        <div class="finding-text">"Returning erythrocytes incubated with 200 mM glucose and DMF to a low-glucose medium devoid of DMF caused a decrease in the amount of glycated haemoglobin, a transient increase in FN3P-Hb and a net decrease in the sum (glycated haemoglobin+FN3P-Hb)."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Second step is spontaneous decomposition of fructosamine 3-phosphate to free amine, 3-deoxyglucosone, and Pi.</div>
                        
                        <div class="finding-text">"The second step of this &#39;deglycation&#39; process is most likely a spontaneous decomposition of the fructosamine 3-phosphate residues to a free amine, 3-deoxyglucosone and P(i)."</div>
                        
                    </li>
                    
                </ul>
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        <a href="https://pubmed.ncbi.nlm.nih.gov/21492153" target="_blank" class="term-link">
                            PMID:21492153
                        </a>
                        
                    </span>
                </div>
                
                <div class="reference-title">Analysis of proteomic changes induced upon cellular differentiation of the human intestinal cell line Caco-2.</div>
                
                
                <ul class="findings-list">
                    
                    <li class="finding-item">
                        <div class="finding-statement">High-throughput proteomics study comparing proliferating and differentiated Caco-2 cells.</div>
                        
                        <div class="finding-text">"The proteome of proliferating Caco-2 cells was compared with that of fully differentiated cells."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Two-dimensional gel analysis identified 53 differentially regulated proteins during differentiation.</div>
                        
                        <div class="finding-text">"Two-dimensional gel analysis yielded 53 proteins that were differently regulated during the differentiation process."</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Study provides expression correlation data but no mechanistic link to differentiation.</div>
                        
                        <div class="finding-text">"Thus, the proteomic approach in combination with a literature-based pathway analysis yielded valuable information about the differentiation process of Caco-2 cells on the molecular level"</div>
                        
                    </li>
                    
                </ul>
                
            </div>
            
            <div class="reference-item">
                <div class="reference-header">
                    <span class="reference-id">
                        
                        file:human/FN3K/FN3K-deep-research-perplexity.md
                        
                    </span>
                </div>
                
                <div class="reference-title">Deep research on FN3K from Perplexity</div>
                
                
                <ul class="findings-list">
                    
                    <li class="finding-item">
                        <div class="finding-statement">FN3K exhibits highly specific substrate recognition with preference for fructose-lysine residues and 10-100x higher affinity for epsilon-lysine vs N-terminal modifications.</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Structural studies show bulky aromatic residues (His288, Trp219, Phe252, Tyr296) create the specialized substrate-binding pocket.</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">FN3K activity is redox-regulated via P-loop cysteine C24 forming disulfide-linked dimers in oxidized state.</div>
                        
                    </li>
                    
                    <li class="finding-item">
                        <div class="finding-statement">Multi-compartmental localization to cytosol, mitochondria, and nucleus supported by multi-omics studies.</div>
                        
                    </li>
                    
                </ul>
                
            </div>
            
        </div>
    </div>
    


    

    

    

    <!-- Additional Documentation Sections -->
    
    <div class="section">
        <h2 class="section-title">üìö Additional Documentation</h2>
        
        <details class="markdown-section">
            <summary style="display: flex; justify-content: space-between; align-items: center; cursor: pointer;">
                <div style="flex: 1;">
                    <h3 style="display: inline;">Deep Research Falcon</h3>
                    <span style="font-size: 0.8rem; color: #666; margin-left: 1rem;">(FN3K-deep-research-falcon.md)</span>
                </div>
                <div class="vote-buttons" data-g="Q9H479" data-a="DOC: Deep Research Falcon" data-r="" data-act="DOCUMENTATION" style="display: flex; gap: 0.25rem;">
                    <button class="vote-btn" data-v="up" title="This documentation is helpful">üëç</button>
                    <button class="vote-btn" data-v="down" title="This documentation needs improvement">üëé</button>
                </div>
            </summary>
            <div class="markdown-content">
                <hr />
<p>provider: falcon<br />
model: Edison Scientific Literature<br />
cached: false<br />
start_time: '2025-12-04T10:31:18.257915'<br />
end_time: '2025-12-04T10:39:01.007021'<br />
duration_seconds: 462.75<br />
template_file: templates/gene_research_go_focused.md<br />
template_variables:<br />
  organism: human<br />
  gene_id: FN3K<br />
  gene_symbol: FN3K<br />
  uniprot_accession: Q9H479<br />
  protein_description: 'RecName: Full=Fructosamine-3-kinase {ECO:0000303|PubMed:11016445};<br />
    EC=2.7.1.171 {ECO:0000269|PubMed:11016445, ECO:0000269|PubMed:11522682}; AltName:<br />
    Full=Protein-psicosamine 3-kinase FN3K {ECO:0000305}; AltName: Full=Protein-ribulosamine<br />
    3-kinase FN3K {ECO:0000305}; EC=2.7.1.172 {ECO:0000269|PubMed:14633848};'<br />
  gene_info: Name=FN3K {ECO:0000303|PubMed:14633848, ECO:0000312|HGNC:HGNC:24822};<br />
  organism_full: Homo sapiens (Human).<br />
  protein_family: Belongs to the fructosamine kinase family. .<br />
  protein_domains: Fructo-/Ketosamine-3-kinase. (IPR016477); Kinase-like_dom_sf. (IPR011009);<br />
    Fructosamin_kin (PF03881)<br />
provider_config:<br />
  timeout: 600<br />
  max_retries: 3<br />
  parameters:<br />
    allowed_domains: []<br />
    temperature: 0.1<br />
citation_count: 36</p>
<hr />
<h2 id="question">Question</h2>
<h1 id="gene-research-for-functional-annotation">Gene Research for Functional Annotation</h1>
<h2 id="critical-geneprotein-identification-context">‚ö†Ô∏è CRITICAL: Gene/Protein Identification Context</h2>
<p><strong>BEFORE YOU BEGIN RESEARCH:</strong> You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.</p>
<h3 id="target-geneprotein-identity-from-uniprot">Target Gene/Protein Identity (from UniProt):</h3>
<ul>
<li><strong>UniProt Accession:</strong> Q9H479</li>
<li><strong>Protein Description:</strong> RecName: Full=Fructosamine-3-kinase {ECO:0000303|PubMed:11016445}; EC=2.7.1.171 {ECO:0000269|PubMed:11016445, ECO:0000269|PubMed:11522682}; AltName: Full=Protein-psicosamine 3-kinase FN3K {ECO:0000305}; AltName: Full=Protein-ribulosamine 3-kinase FN3K {ECO:0000305}; EC=2.7.1.172 {ECO:0000269|PubMed:14633848};</li>
<li><strong>Gene Information:</strong> Name=FN3K {ECO:0000303|PubMed:14633848, ECO:0000312|HGNC:HGNC:24822};</li>
<li><strong>Organism (full):</strong> Homo sapiens (Human).</li>
<li><strong>Protein Family:</strong> Belongs to the fructosamine kinase family. .</li>
<li><strong>Key Domains:</strong> Fructo-/Ketosamine-3-kinase. (IPR016477); Kinase-like_dom_sf. (IPR011009); Fructosamin_kin (PF03881)</li>
</ul>
<h3 id="mandatory-verification-steps">MANDATORY VERIFICATION STEPS:</h3>
<ol>
<li><strong>Check if the gene symbol "FN3K" matches the protein description above</strong></li>
<li><strong>Verify the organism is correct:</strong> Homo sapiens (Human).</li>
<li><strong>Check if protein family/domains align with what you find in literature</strong></li>
<li><strong>If you find literature for a DIFFERENT gene with the same or similar symbol, STOP</strong></li>
</ol>
<h3 id="if-gene-symbol-is-ambiguous-or-you-cannot-find-relevant-literature">If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:</h3>
<p><strong>DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.</strong> Instead:<br />
- State clearly: "The gene symbol 'FN3K' is ambiguous or literature is limited for this specific protein"<br />
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")<br />
- Describe the protein based ONLY on the UniProt information provided above<br />
- Suggest that the protein function can be inferred from domain/family information</p>
<h3 id="research-target">Research Target:</h3>
<p>Please provide a comprehensive research report on the gene <strong>FN3K</strong> (gene ID: FN3K, UniProt: Q9H479) in human.</p>
<p>The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.</p>
<p>You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement<br />
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.</p>
<p>We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.</p>
<p>We are interested in where in or outside the cell the gene product carries out its function.</p>
<p>We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.</p>
<p>Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.</p>
<h2 id="output">Output</h2>
<p>Question: You are an expert researcher providing comprehensive, well-cited information.</p>
<p>Provide detailed information focusing on:<br />
1. Key concepts and definitions with current understanding<br />
2. Recent developments and latest research (prioritize 2023-2024 sources)<br />
3. Current applications and real-world implementations<br />
4. Expert opinions and analysis from authoritative sources<br />
5. Relevant statistics and data from recent studies</p>
<p>Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.<br />
Always prioritize recent, authoritative sources and provide specific citations for all major claims.</p>
<h1 id="gene-research-for-functional-annotation_1">Gene Research for Functional Annotation</h1>
<h2 id="critical-geneprotein-identification-context_1">‚ö†Ô∏è CRITICAL: Gene/Protein Identification Context</h2>
<p><strong>BEFORE YOU BEGIN RESEARCH:</strong> You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.</p>
<h3 id="target-geneprotein-identity-from-uniprot_1">Target Gene/Protein Identity (from UniProt):</h3>
<ul>
<li><strong>UniProt Accession:</strong> Q9H479</li>
<li><strong>Protein Description:</strong> RecName: Full=Fructosamine-3-kinase {ECO:0000303|PubMed:11016445}; EC=2.7.1.171 {ECO:0000269|PubMed:11016445, ECO:0000269|PubMed:11522682}; AltName: Full=Protein-psicosamine 3-kinase FN3K {ECO:0000305}; AltName: Full=Protein-ribulosamine 3-kinase FN3K {ECO:0000305}; EC=2.7.1.172 {ECO:0000269|PubMed:14633848};</li>
<li><strong>Gene Information:</strong> Name=FN3K {ECO:0000303|PubMed:14633848, ECO:0000312|HGNC:HGNC:24822};</li>
<li><strong>Organism (full):</strong> Homo sapiens (Human).</li>
<li><strong>Protein Family:</strong> Belongs to the fructosamine kinase family. .</li>
<li><strong>Key Domains:</strong> Fructo-/Ketosamine-3-kinase. (IPR016477); Kinase-like_dom_sf. (IPR011009); Fructosamin_kin (PF03881)</li>
</ul>
<h3 id="mandatory-verification-steps_1">MANDATORY VERIFICATION STEPS:</h3>
<ol>
<li><strong>Check if the gene symbol "FN3K" matches the protein description above</strong></li>
<li><strong>Verify the organism is correct:</strong> Homo sapiens (Human).</li>
<li><strong>Check if protein family/domains align with what you find in literature</strong></li>
<li><strong>If you find literature for a DIFFERENT gene with the same or similar symbol, STOP</strong></li>
</ol>
<h3 id="if-gene-symbol-is-ambiguous-or-you-cannot-find-relevant-literature_1">If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:</h3>
<p><strong>DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.</strong> Instead:<br />
- State clearly: "The gene symbol 'FN3K' is ambiguous or literature is limited for this specific protein"<br />
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")<br />
- Describe the protein based ONLY on the UniProt information provided above<br />
- Suggest that the protein function can be inferred from domain/family information</p>
<h3 id="research-target_1">Research Target:</h3>
<p>Please provide a comprehensive research report on the gene <strong>FN3K</strong> (gene ID: FN3K, UniProt: Q9H479) in human.</p>
<p>The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.</p>
<p>You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement<br />
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.</p>
<p>We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.</p>
<p>We are interested in where in or outside the cell the gene product carries out its function.</p>
<p>We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.</p>
<p>Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.</p>
<p>Research plan and verification<br />
We verified the target as human FN3K (UniProt Q9H479), fructosamine-3-kinase, a protein kinase‚Äìlike (PKL) fold enzyme in the fructosamine kinase family. Recent structural and mechanistic studies explicitly characterize human FN3K (HsFN3K) and distinguish it from its paralog FN3KRP, with organism Homo sapiens (human) confirmed (PDBs 9CX8, 9CXV, 9CXW, 9CXM, 9CXN, 9CXO) (garg2025themolecularbasis pages 12-13). Redox regulation is a conserved feature in the FN3K family (shrestha2020aredoxactiveswitch pages 1-2).</p>
<p>Comprehensive research report<br />
1) Key concepts and definitions<br />
- Gene/protein identity and family: FN3K encodes fructosamine-3-kinase, a conserved repair enzyme that adopts the protein kinase‚Äìlike fold. FN3Ks are evolutionarily related to eukaryotic protein kinases and phosphorylate sugars attached to lysine residues in proteins (ketosamines/fructosamines), reversing early glycation damage (deglycation) (Science Signaling, 2020; URL: https://doi.org/10.1126/scisignal.aax6313; published Jul 14, 2020) (shrestha2020aredoxactiveswitch pages 1-2). Human structural work (Nature Communications, 2025) confirms canonical kinase features and substrate-binding elements (URL: https://doi.org/10.1038/s41467-025-56207-z; published Jan 6, 2025) (garg2025themolecularbasis pages 12-13, garg2025themolecularbasis pages 1-2).<br />
- Primary enzymatic reaction (deglycation): FN3K transfers the Œ≥-phosphate of ATP to the 3‚Ä≤-hydroxyl of the fructose-lysine (Amadori) moiety on glycated lysines. The fructosamine-3-phosphate is unstable and decomposes to release inorganic phosphate and the dicarbonyl 3-deoxyglucosone, regenerating the free lysine (Nature Communications 2025; URL above) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13). Foundational descriptions of ketosamine/fructosamine phosphorylation and 3-deoxyglucosone formation are consistent with multi-omics reviews (NPJ Systems Biology &amp; Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; published Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 65-71).<br />
- Substrate scope: HsFN3K reverses protein glycation by site-specific phosphorylation of fructose-lysine; activity on a small-molecule mimic (1-deoxy-1-morpholino-D-fructose, DMF) is robust. The paralog FN3KRP in mammals is a ketosamine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines, underscoring substrate differences within the family (supported by structural/mechanistic reviews and ancestral reconstruction analysis; bioRxiv, 2025; URL: https://doi.org/10.1101/2025.07.30.667714; posted Jul 30, 2025) (garg2025themolecularbasis pages 1-2, matlack2025ancestralproteinreconstruction pages 15-18, shrestha2023elucidatingtheunderstudied pages 90-95).</p>
<p>2) Recent developments and latest research (2023‚Äì2024 priority)<br />
- Human FN3K structures and mechanism: Multiple human FN3K crystal structures were determined (apo and with nucleotide/sugar mimics), revealing features important for substrate recognition and catalysis and providing a framework for inhibitor design (Nature Communications, 2025; PDB: 9CX8, 9CXV, 9CXW, 9CXM, 9CXN, 9CXO; URL: https://doi.org/10.1038/s41467-025-56207-z; Jan 2025) (garg2025themolecularbasis pages 12-13, garg2025themolecularbasis pages 1-2).<br />
- Multi-omics pathway links: An FN3K CRISPR KO in human HepG2 cells, integrated with transcriptomics, metabolomics, and interactomics, connected FN3K to oxidative stress response, lipid biosynthesis (cholesterol and fatty acids), and carbon/co-factor metabolism. The study reports mitochondrial localization and enrichment of NAD-binding proteins, with experimental evidence that HsFN3K binds NAD compounds in a metal- and concentration-dependent manner (NPJ Systems Biology &amp; Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 17-22, shrestha2023elucidatingtheunderstudied pages 65-71).<br />
- Redox regulation: A conserved redox-active ‚Äúdisulfide switch‚Äù centered on a P-loop cysteine regulates FN3K activity and oligomerization; reduction activates the enzyme. This mechanism was defined structurally in Arabidopsis FN3K and functionally extends to human FN3K (Science Signaling, 2020; URL: https://doi.org/10.1126/scisignal.aax6313; Jul 14, 2020) (shrestha2020aredoxactiveswitch pages 1-2). The redox model and metabolic feedback were further explored in 2023 analyses (shrestha2023elucidatingtheunderstudied pages 45-51).<br />
- Cancer biology and FN3K‚ÄìNRF2 axis: Computational and cellular studies suggest FN3K modulates NRF2-driven antioxidant signaling. Drug screens in breast cancer cells showed several approved anticancer drugs alter FN3K expression and NRF2 signaling (PLOS ONE, 2023; URL: https://doi.org/10.1371/journal.pone.0283705; Nov 1, 2023) (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2). In renal cell carcinoma, amiloride reduced FN3K expression and restored sunitinib sensitivity; FN3K appeared to interact with VEGFR2 (iScience, 2024; URL: https://doi.org/10.1016/j.isci.2024.109997; Jun 18, 2024) (shrestha2023elucidatingtheunderstudied pages 65-71).</p>
<p>3) Current applications and real-world implementations<br />
- Ex vivo tissue deglycation: Combined enzymatic treatment with FN3K and fructosyl-amino acid oxidase (FAOD) reduced AGE-associated autofluorescence in human skin specimens. FN3K or FAOD alone decreased AF by ~31‚Äì33%, while the combination achieved a 43% decrease; hypertrophic scar elasticity improved after FN3K treatment (International Journal of Molecular Sciences, 2023; URL: https://doi.org/10.3390/ijms24108981; May 15, 2023) (decker2023enzymaticdeglycationof pages 4-7).<br />
- Therapeutic exploration: Computational screens and repurposing efforts have sought FN3K inhibitors/modulators, motivated by putative roles in redox homeostasis and cancer resistance (PLOS ONE, 2023; URL: https://doi.org/10.1371/journal.pone.0283705; Nov 1, 2023) (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2). Restoration of TKI sensitivity in RCC via reducing FN3K expression (amiloride) illustrates a potential translational angle (iScience, 2024; URL above; Jun 18, 2024) (shrestha2023elucidatingtheunderstudied pages 65-71).</p>
<p>4) Expert opinions and analysis from authoritative sources<br />
- Structural enzymology and regulation: The Science Signaling study articulates a generalizable redox regulatory mechanism in the FN3K family with clear evolutionary support and structural basis, expanding the regulatory repertoire of the kinase superfamily (AAAS journal; 2020) (shrestha2020aredoxactiveswitch pages 1-2). The Nature Communications human structural series provides high-resolution mechanistic insights enabling rational inhibitor design (2025; Springer Nature) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13).<br />
- Systems-level function: The NPJ Systems Biology &amp; Applications study (Nature Portfolio) integrates multi-omics to position FN3K within redox, lipid, and NAD-linked metabolic networks, arguing for mitochondrial association and NAD interactions as potential mechanisms connecting deglycation to metabolism (2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 17-22, shrestha2023elucidatingtheunderstudied pages 65-71).</p>
<p>5) Relevant statistics and data (recent studies)<br />
- Structural/biochemical metrics (human): HsFN3K forms redox-sensitive dimer/monomer species; a dimeric species exhibited ~60% higher kinase activity on a small-molecule fructosamine mimic (DMF) than monomer; both had similar Tm (~54 ¬∞C). Dimer converted to monomer under reducing conditions within ~20 min (Nature Communications, 2025; URL: https://doi.org/10.1038/s41467-025-56207-z; Jan 6, 2025) (garg2025themolecularbasis pages 1-2).<br />
- Redox activation (plant ortholog): Reduction of intermolecular disulfides in AtFN3K activated the enzyme (&gt;40-fold), implicating a conserved redox switch that is present in human FN3K (Science Signaling, 2020; URL: https://doi.org/10.1126/scisignal.aax6313; Jul 14, 2020) (shrestha2020aredoxactiveswitch pages 1-2, shrestha2023elucidatingtheunderstudied pages 45-51).<br />
- Ex vivo skin deglycation: Average AF decrease following treatment was 31% with FN3K, 33% with FAOD, and 43% with combined FN3K+FAOD; scar elasticity improved after FN3K (IJMS, 2023; URL: https://doi.org/10.3390/ijms24108981; May 15, 2023) (decker2023enzymaticdeglycationof pages 4-7).<br />
- Genetic associations with HbA1c and related traits: Open Targets collates strong genetic association evidence linking FN3K (and FN3KRP) loci to HbA1c measurement and related hematologic traits, with FN3K showing a high association score for ‚ÄúHbA1c measurement‚Äù (EFO_0004541) based on GWAS credible sets (Open Targets Platform; accessed 2025; see evidence PMIDs in platform record) (OpenTargets Search: -FN3K). A 2024 GWAS-based cFDR analysis highlights rs1046896 in FN3KRP as an HbA1c-associated pleiotropic locus (Biomedicines, 2024; URL: https://doi.org/10.3390/biomedicines12010157; Jan 8, 2024) (cheng2024sharedgeneticsbetween pages 4-5, cheng2024sharedgeneticsbetween pages 5-7).</p>
<p>Function, substrates, and specificity (focused annotation)<br />
- Reaction and products: HsFN3K phosphorylates the O3‚Ä≤ position of fructose-lysine (Amadori) groups on glycated proteins, forming fructosamine-3-phosphate that decomposes to release phosphate and 3-deoxyglucosone, thereby restoring unmodified lysine and reversing early glycation (Nature Communications 2025; URL: https://doi.org/10.1038/s41467-025-56207-z; Jan 6, 2025) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13). Multi-omics reviews concur and emphasize that 3-deoxyglucosone may affect cellular redox, implying feedback onto FN3K regulation (NPJ Systems Biology &amp; Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 65-71).<br />
- Substrate class: HsFN3K acts on protein-bound fructosamines and also phosphorylates small-molecule fructosamine mimics (e.g., DMF) used for mechanistic/structural studies (Nature Communications, 2025; URL above) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13). In contrast, the mammalian paralog FN3KRP displays ketosamine preference (ribulosamines/psicosamines), not fructosamines, consistent with ancestral and comparative analyses (bioRxiv, 2025; URL: https://doi.org/10.1101/2025.07.30.667714; Jul 30, 2025; and curated reviews) (matlack2025ancestralproteinreconstruction pages 15-18, shrestha2023elucidatingtheunderstudied pages 90-95).</p>
<p>Localization and regulation<br />
- Subcellular localization: Human FN3K has been localized to mitochondria in human cells in a multi-omics context; presence in erythrocytes and serum is also reported (NPJ Systems Biology &amp; Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 45-51).<br />
- Redox-sensitive control: A conserved P-loop cysteine forms an intermolecular disulfide in an inhibited dimeric state; reduction breaks the disulfide, activates the kinase, and shifts oligomerization. This redox switch is well supported structurally in AtFN3K and functionally conserved in HsFN3K (Science Signaling, 2020; URL: https://doi.org/10.1126/scisignal.aax6313; Jul 14, 2020) (shrestha2020aredoxactiveswitch pages 1-2, shrestha2023elucidatingtheunderstudied pages 45-51). Human structural work shows redox-sensitive dimer/monomer states with differential activity (Nature Communications, 2025; URL above) (garg2025themolecularbasis pages 1-2).<br />
- NAD compound binding: Multi-omics and biochemistry indicate HsFN3K specifically binds NAD compounds in a metal- and concentration-dependent manner, suggesting a link to NAD-mediated energy metabolism and redox balance (NPJ Systems Biology &amp; Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 17-22, shrestha2023elucidatingtheunderstudied pages 65-71).</p>
<p>Pathways and interactors<br />
- NRF2 axis: FN3K-mediated deglycation has been linked to maintaining NRF2 function; computational and cell-based studies show modulation of FN3K alters NRF2-driven antioxidant signaling (PLOS ONE, 2023; URL: https://doi.org/10.1371/journal.pone.0283705; Nov 1, 2023) (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2). Systems studies position FN3K within oxidative stress and lipid/co-factor metabolism pathways (NPJ Systems Biology &amp; Applications, 2024; URL: https://doi.org/10.1038/s41540-024-00390-0; Jun 6, 2024) (shrestha2024multiomicsrevealsnew pages 1-3).<br />
- VEGFR2 in RCC: In renal cell carcinoma models, FN3K expression affected sunitinib response; evidence of interaction with VEGFR2 was presented, though VEGFR2 deglycation was not definitively proven (iScience, 2024; URL: https://doi.org/10.1016/j.isci.2024.109997; Jun 18, 2024) (shrestha2023elucidatingtheunderstudied pages 65-71).</p>
<p>Disease relevance and genetics<br />
- Glycemic traits and HbA1c: Strong GWAS-based evidence links the FN3K/FN3KRP locus to HbA1c and related traits. Open Targets aggregates multiple GWAS credible-set evidences supporting FN3K association with ‚ÄúHbA1c measurement‚Äù (EFO_0004541) (Open Targets Platform; accessed 2025) (OpenTargets Search: -FN3K). A 2024 cFDR GWAS analysis highlights rs1046896 in FN3KRP as highly associated with HbA1c (Biomedicines, 2024; URL: https://doi.org/10.3390/biomedicines12010157; Jan 8, 2024) (cheng2024sharedgeneticsbetween pages 4-5, cheng2024sharedgeneticsbetween pages 5-7). Together with historical literature tying FN3K activity to erythrocyte deglycation, these genetic data support a role for the FN3K/FN3KRP region in hemoglobin glycation metrics (garg2025themolecularbasis pages 12-13).<br />
- Cancer and redox: FN3K expression is elevated in some tumors and influences therapeutic resistance via redox/NRF2-linked pathways; reducing FN3K expression can resensitize RCC to sunitinib (iScience, 2024; URL above) (shrestha2023elucidatingtheunderstudied pages 65-71). Computational/experimental screens implicate clinically used drugs in modulating FN3K expression and NRF2 signaling in breast cancer cells (PLOS ONE, 2023; URL above) (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2).</p>
<p>Open questions and cautions<br />
- While human structures now clarify substrate recognition, quantification of in-cell substrate scope (protein targets, free vs protein-bound selectivity) and NAD binding constants remain to be defined. The VEGFR2 interaction requires definitive demonstration of direct deglycation (iScience 2024) (shrestha2023elucidatingtheunderstudied pages 65-71). Genetic associations near FN3K/FN3KRP influencing HbA1c are strong, but causal mechanisms (e.g., effects on erythrocyte glycation dynamics vs erythropoiesis) need further resolution (Open Targets; 2025) (OpenTargets Search: -FN3K).</p>
<p>References (URLs and dates)<br />
- Shrestha et al., A redox-active switch in fructosamine-3-kinases. Science Signaling. Jul 14, 2020. URL: https://doi.org/10.1126/scisignal.aax6313 (shrestha2020aredoxactiveswitch pages 1-2).<br />
- Garg et al., The molecular basis of human FN3K mediated phosphorylation of glycated substrates. Nature Communications. Jan 6, 2025. URL: https://doi.org/10.1038/s41467-025-56207-z (includes PDB 9CX8, 9CXV, 9CXW, 9CXM, 9CXN, 9CXO) (garg2025themolecularbasis pages 1-2, garg2025themolecularbasis pages 12-13).<br />
- Shrestha et al., Multi-omics reveals new links between FN3K and core metabolic pathways. NPJ Systems Biology &amp; Applications. Jun 6, 2024. URL: https://doi.org/10.1038/s41540-024-00390-0 (shrestha2024multiomicsrevealsnew pages 1-3, shrestha2023elucidatingtheunderstudied pages 65-71, shrestha2023elucidatingtheunderstudied pages 17-22).<br />
- Beeraka et al., Screening FN3K inhibitors; modulation of NRF2 signaling. PLOS ONE. Nov 1, 2023. URL: https://doi.org/10.1371/journal.pone.0283705 (beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2).<br />
- Bai et al., Amiloride reduces FN3K expression to restore sunitinib sensitivity in RCC. iScience. Jun 18, 2024. URL: https://doi.org/10.1016/j.isci.2024.109997 (shrestha2023elucidatingtheunderstudied pages 65-71).<br />
- De Decker et al., Enzymatic deglycation of damaged skin by FN3K and FAOD. International Journal of Molecular Sciences. May 15, 2023. URL: https://doi.org/10.3390/ijms24108981 (decker2023enzymaticdeglycationof pages 4-7).<br />
- Matlack et al., Ancestral protein reconstruction reveals mechanisms of FN3K substrate specificity. bioRxiv. Jul 30, 2025. URL: https://doi.org/10.1101/2025.07.30.667714 (supports FN3K vs FN3KRP substrate distinctions) (matlack2025ancestralproteinreconstruction pages 15-18, matlack2025ancestralproteinreconstruction pages 12-15).<br />
- Open Targets Platform (accessed 2025): FN3K/FN3KRP genetic associations with HbA1c measurement and related traits. URL: https://platform.opentargets.org (OpenTargets Search: -FN3K).<br />
- Additional identity and localization notes: CRISPR-KO metabolomics and mentions of erythrocyte/serum presence (2023‚Äì2024 analyses) (shrestha2023elucidatingtheunderstudied pages 45-51, shrestha2024multiomicsrevealsnew pages 1-3).</p>
<p>Conclusion<br />
Human FN3K (Q9H479) is a kinase-like deglycation enzyme that phosphorylates protein-bound fructosamines to promote deglycation, is regulated by a conserved redox disulfide switch, and likely interfaces with mitochondrial/NAD-linked metabolism. Recent human structures now enable rational inhibitor design. Genetic associations implicate the FN3K/FN3KRP locus in HbA1c variation. Early ex vivo applications (skin) and oncology findings (RCC sensitivity) suggest translational potential, while key mechanistic questions‚Äîphysiologic substrates, NAD binding parameters, and pathway wiring‚Äîremain active areas of research (shrestha2020aredoxactiveswitch pages 1-2, garg2025themolecularbasis pages 12-13, shrestha2024multiomicsrevealsnew pages 1-3, OpenTargets Search: -FN3K, decker2023enzymaticdeglycationof pages 4-7, shrestha2023elucidatingtheunderstudied pages 65-71, beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2).</p>
<p>References</p>
<ol>
<li>
<p>(garg2025themolecularbasis pages 12-13): Ankur Garg, Kin Fan On, Yang Xiao, Elad Elkayam, Paolo Cifani, Yael David, and Leemor Joshua-Tor. The molecular basis of human fn3k mediated phosphorylation of glycated substrates. Nature Communications, Jan 2025. URL: https://doi.org/10.1038/s41467-025-56207-z, doi:10.1038/s41467-025-56207-z. This article has 5 citations and is from a highest quality peer-reviewed journal.</p>
</li>
<li>
<p>(shrestha2020aredoxactiveswitch pages 1-2): Safal Shrestha, Samiksha Katiyar, Carlos E. Sanz-Rodriguez, Nolan R. Kemppinen, Hyun W. Kim, Renuka Kadirvelraj, Charalampos Panagos, Neda Keyhaninejad, Maxwell Colonna, Pradeep Chopra, Dominic P. Byrne, Geert J. Boons, Esther van der Knaap, Patrick A. Eyers, Arthur S. Edison, Zachary A. Wood, and Natarajan Kannan. A redox-active switch in fructosamine-3-kinases expands the regulatory repertoire of the protein kinase superfamily. Science Signaling, Jul 2020. URL: https://doi.org/10.1126/scisignal.aax6313, doi:10.1126/scisignal.aax6313. This article has 24 citations and is from a domain leading peer-reviewed journal.</p>
</li>
<li>
<p>(garg2025themolecularbasis pages 1-2): Ankur Garg, Kin Fan On, Yang Xiao, Elad Elkayam, Paolo Cifani, Yael David, and Leemor Joshua-Tor. The molecular basis of human fn3k mediated phosphorylation of glycated substrates. Nature Communications, Jan 2025. URL: https://doi.org/10.1038/s41467-025-56207-z, doi:10.1038/s41467-025-56207-z. This article has 5 citations and is from a highest quality peer-reviewed journal.</p>
</li>
<li>
<p>(shrestha2024multiomicsrevealsnew pages 1-3): Safal Shrestha, Rahil Taujale, Samiksha Katiyar, and Natarajan Kannan. Multi-omics reveals new links between fructosamine-3-kinase (fn3k) and core metabolic pathways. NPJ Systems Biology and Applications, Jun 2024. URL: https://doi.org/10.1038/s41540-024-00390-0, doi:10.1038/s41540-024-00390-0. This article has 3 citations and is from a poor quality or predatory journal.</p>
</li>
<li>
<p>(shrestha2023elucidatingtheunderstudied pages 65-71): S Shrestha. Elucidating the understudied fructosamine-3-kinase (fn3k) family: a combined experimental and computational study on structure, function, evolution, and ‚Ä¶. Unknown journal, 2023.</p>
</li>
<li>
<p>(matlack2025ancestralproteinreconstruction pages 15-18): Jenet K. Matlack, Robert E. Miner, Jameela Lokhandwala, and Jennifer M. Binning. Ancestral protein reconstruction reveals the mechanism of substrate specificity in fn3k-mediated deglycation. bioRxiv, Jul 2025. URL: https://doi.org/10.1101/2025.07.30.667714, doi:10.1101/2025.07.30.667714. This article has 0 citations and is from a poor quality or predatory journal.</p>
</li>
<li>
<p>(shrestha2023elucidatingtheunderstudied pages 90-95): S Shrestha. Elucidating the understudied fructosamine-3-kinase (fn3k) family: a combined experimental and computational study on structure, function, evolution, and ‚Ä¶. Unknown journal, 2023.</p>
</li>
<li>
<p>(shrestha2023elucidatingtheunderstudied pages 17-22): S Shrestha. Elucidating the understudied fructosamine-3-kinase (fn3k) family: a combined experimental and computational study on structure, function, evolution, and ‚Ä¶. Unknown journal, 2023.</p>
</li>
<li>
<p>(shrestha2023elucidatingtheunderstudied pages 45-51): S Shrestha. Elucidating the understudied fructosamine-3-kinase (fn3k) family: a combined experimental and computational study on structure, function, evolution, and ‚Ä¶. Unknown journal, 2023.</p>
</li>
<li>
<p>(beeraka2023screeningfructosamine3kinase(fn3k) pages 1-2): Narasimha M. Beeraka, Jin Zhang, Subhankar Mandal, Hemanth Vikram P. R., Junqi Liu, Namitha B. M., Di Zhao, Prashanth Vishwanath, Gurupadayya B. M., and Ruitai Fan. Screening fructosamine-3-kinase (fn3k) inhibitors, a deglycating enzyme of oncogenic nrf2: human fn3k homology modelling, docking and molecular dynamics simulations. PLOS ONE, 18:e0283705, Nov 2023. URL: https://doi.org/10.1371/journal.pone.0283705, doi:10.1371/journal.pone.0283705. This article has 10 citations and is from a peer-reviewed journal.</p>
</li>
<li>
<p>(decker2023enzymaticdeglycationof pages 4-7): Ignace De Decker, Margo Notebaert, Marijn M. Speeckaert, Karel E. Y. Claes, Phillip Blondeel, Elisabeth Van Aken, Jo Van Dorpe, Filip De Somer, Margaux Heintz, Stan Monstrey, and Joris R. Delanghe. Enzymatic deglycation of damaged skin by means of combined treatment of fructosamine-3-kinase and fructosyl-amino acid oxidase. International Journal of Molecular Sciences, 24:8981, May 2023. URL: https://doi.org/10.3390/ijms24108981, doi:10.3390/ijms24108981. This article has 5 citations and is from a poor quality or predatory journal.</p>
</li>
<li>
<p>(OpenTargets Search: -FN3K): Open Targets Query (-FN3K, 10 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.</p>
</li>
<li>
<p>(cheng2024sharedgeneticsbetween pages 4-5): Yuan-Fang Cheng, Cheng-Yi Yang, and Meng-Che Tsai. Shared genetics between age at menarche and type 2 diabetes mellitus: genome-wide genetic correlation study. Biomedicines, 12:157, Jan 2024. URL: https://doi.org/10.3390/biomedicines12010157, doi:10.3390/biomedicines12010157. This article has 1 citations and is from a poor quality or predatory journal.</p>
</li>
<li>
<p>(cheng2024sharedgeneticsbetween pages 5-7): Yuan-Fang Cheng, Cheng-Yi Yang, and Meng-Che Tsai. Shared genetics between age at menarche and type 2 diabetes mellitus: genome-wide genetic correlation study. Biomedicines, 12:157, Jan 2024. URL: https://doi.org/10.3390/biomedicines12010157, doi:10.3390/biomedicines12010157. This article has 1 citations and is from a poor quality or predatory journal.</p>
</li>
<li>
<p>(matlack2025ancestralproteinreconstruction pages 12-15): Jenet K. Matlack, Robert E. Miner, Jameela Lokhandwala, and Jennifer M. Binning. Ancestral protein reconstruction reveals the mechanism of substrate specificity in fn3k-mediated deglycation. bioRxiv, Jul 2025. URL: https://doi.org/10.1101/2025.07.30.667714, doi:10.1101/2025.07.30.667714. This article has 0 citations and is from a poor quality or predatory journal.</p>
</li>
</ol>
<h2 id="citations">Citations</h2>
<ol>
<li>garg2025themolecularbasis pages 12-13</li>
<li>shrestha2020aredoxactiveswitch pages 1-2</li>
<li>shrestha2023elucidatingtheunderstudied pages 45-51</li>
<li>shrestha2023elucidatingtheunderstudied pages 65-71</li>
<li>decker2023enzymaticdeglycationof pages 4-7</li>
<li>garg2025themolecularbasis pages 1-2</li>
<li>shrestha2024multiomicsrevealsnew pages 1-3</li>
<li>matlack2025ancestralproteinreconstruction pages 15-18</li>
<li>shrestha2023elucidatingtheunderstudied pages 90-95</li>
<li>shrestha2023elucidatingtheunderstudied pages 17-22</li>
<li>cheng2024sharedgeneticsbetween pages 4-5</li>
<li>cheng2024sharedgeneticsbetween pages 5-7</li>
<li>matlack2025ancestralproteinreconstruction pages 12-15</li>
<li>https://doi.org/10.1126/scisignal.aax6313;</li>
<li>https://doi.org/10.1038/s41467-025-56207-z;</li>
<li>https://doi.org/10.1038/s41540-024-00390-0;</li>
<li>https://doi.org/10.1101/2025.07.30.667714;</li>
<li>https://doi.org/10.1371/journal.pone.0283705;</li>
<li>https://doi.org/10.1016/j.isci.2024.109997;</li>
<li>https://doi.org/10.3390/ijms24108981;</li>
<li>https://doi.org/10.3390/biomedicines12010157;</li>
<li>https://doi.org/10.1126/scisignal.aax6313</li>
<li>https://doi.org/10.1038/s41467-025-56207-z</li>
<li>https://doi.org/10.1038/s41540-024-00390-0</li>
<li>https://doi.org/10.1371/journal.pone.0283705</li>
<li>https://doi.org/10.1016/j.isci.2024.109997</li>
<li>https://doi.org/10.3390/ijms24108981</li>
<li>https://doi.org/10.1101/2025.07.30.667714</li>
<li>https://platform.opentargets.org</li>
<li>https://doi.org/10.1038/s41467-025-56207-z,</li>
<li>https://doi.org/10.1126/scisignal.aax6313,</li>
<li>https://doi.org/10.1038/s41540-024-00390-0,</li>
<li>https://doi.org/10.1101/2025.07.30.667714,</li>
<li>https://doi.org/10.1371/journal.pone.0283705,</li>
<li>https://doi.org/10.3390/ijms24108981,</li>
<li>https://doi.org/10.3390/biomedicines12010157,</li>
</ol>
            </div>
        </details>
        
        <details class="markdown-section">
            <summary style="display: flex; justify-content: space-between; align-items: center; cursor: pointer;">
                <div style="flex: 1;">
                    <h3 style="display: inline;">Deep Research Perplexity</h3>
                    <span style="font-size: 0.8rem; color: #666; margin-left: 1rem;">(FN3K-deep-research-perplexity.md)</span>
                </div>
                <div class="vote-buttons" data-g="Q9H479" data-a="DOC: Deep Research Perplexity" data-r="" data-act="DOCUMENTATION" style="display: flex; gap: 0.25rem;">
                    <button class="vote-btn" data-v="up" title="This documentation is helpful">üëç</button>
                    <button class="vote-btn" data-v="down" title="This documentation needs improvement">üëé</button>
                </div>
            </summary>
            <div class="markdown-content">
                <hr />
<p>provider: perplexity<br />
model: sonar-deep-research<br />
cached: false<br />
start_time: '2025-12-04T10:31:30.456241'<br />
end_time: '2025-12-04T10:34:06.280876'<br />
duration_seconds: 155.82<br />
template_file: templates/gene_research_go_focused.md<br />
template_variables:<br />
  organism: human<br />
  gene_id: FN3K<br />
  gene_symbol: FN3K<br />
  uniprot_accession: Q9H479<br />
  protein_description: 'RecName: Full=Fructosamine-3-kinase {ECO:0000303|PubMed:11016445};<br />
    EC=2.7.1.171 {ECO:0000269|PubMed:11016445, ECO:0000269|PubMed:11522682}; AltName:<br />
    Full=Protein-psicosamine 3-kinase FN3K {ECO:0000305}; AltName: Full=Protein-ribulosamine<br />
    3-kinase FN3K {ECO:0000305}; EC=2.7.1.172 {ECO:0000269|PubMed:14633848};'<br />
  gene_info: Name=FN3K {ECO:0000303|PubMed:14633848, ECO:0000312|HGNC:HGNC:24822};<br />
  organism_full: Homo sapiens (Human).<br />
  protein_family: Belongs to the fructosamine kinase family. .<br />
  protein_domains: Fructo-/Ketosamine-3-kinase. (IPR016477); Kinase-like_dom_sf. (IPR011009);<br />
    Fructosamin_kin (PF03881)<br />
provider_config:<br />
  timeout: 600<br />
  max_retries: 3<br />
  parameters:<br />
    allowed_domains: []<br />
    reasoning_effort: medium<br />
    search_domain_filter: []<br />
    return_citations: true<br />
    temperature: 0.0<br />
citation_count: 38</p>
<hr />
<h2 id="question">Question</h2>
<h1 id="gene-research-for-functional-annotation">Gene Research for Functional Annotation</h1>
<h2 id="critical-geneprotein-identification-context">‚ö†Ô∏è CRITICAL: Gene/Protein Identification Context</h2>
<p><strong>BEFORE YOU BEGIN RESEARCH:</strong> You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.</p>
<h3 id="target-geneprotein-identity-from-uniprot">Target Gene/Protein Identity (from UniProt):</h3>
<ul>
<li><strong>UniProt Accession:</strong> Q9H479</li>
<li><strong>Protein Description:</strong> RecName: Full=Fructosamine-3-kinase {ECO:0000303|PubMed:11016445}; EC=2.7.1.171 {ECO:0000269|PubMed:11016445, ECO:0000269|PubMed:11522682}; AltName: Full=Protein-psicosamine 3-kinase FN3K {ECO:0000305}; AltName: Full=Protein-ribulosamine 3-kinase FN3K {ECO:0000305}; EC=2.7.1.172 {ECO:0000269|PubMed:14633848};</li>
<li><strong>Gene Information:</strong> Name=FN3K {ECO:0000303|PubMed:14633848, ECO:0000312|HGNC:HGNC:24822};</li>
<li><strong>Organism (full):</strong> Homo sapiens (Human).</li>
<li><strong>Protein Family:</strong> Belongs to the fructosamine kinase family. .</li>
<li><strong>Key Domains:</strong> Fructo-/Ketosamine-3-kinase. (IPR016477); Kinase-like_dom_sf. (IPR011009); Fructosamin_kin (PF03881)</li>
</ul>
<h3 id="mandatory-verification-steps">MANDATORY VERIFICATION STEPS:</h3>
<ol>
<li><strong>Check if the gene symbol "FN3K" matches the protein description above</strong></li>
<li><strong>Verify the organism is correct:</strong> Homo sapiens (Human).</li>
<li><strong>Check if protein family/domains align with what you find in literature</strong></li>
<li><strong>If you find literature for a DIFFERENT gene with the same or similar symbol, STOP</strong></li>
</ol>
<h3 id="if-gene-symbol-is-ambiguous-or-you-cannot-find-relevant-literature">If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:</h3>
<p><strong>DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.</strong> Instead:<br />
- State clearly: "The gene symbol 'FN3K' is ambiguous or literature is limited for this specific protein"<br />
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")<br />
- Describe the protein based ONLY on the UniProt information provided above<br />
- Suggest that the protein function can be inferred from domain/family information</p>
<h3 id="research-target">Research Target:</h3>
<p>Please provide a comprehensive research report on the gene <strong>FN3K</strong> (gene ID: FN3K, UniProt: Q9H479) in human.</p>
<p>The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.</p>
<p>You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement<br />
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.</p>
<p>We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.</p>
<p>We are interested in where in or outside the cell the gene product carries out its function.</p>
<p>We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.</p>
<p>Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.</p>
<h2 id="output">Output</h2>
<p><think><br />
Let me analyze this query and the provided search results to create a comprehensive research report on the FN3K gene (UniProt Q9H479, human fructosamine-3-kinase).</p>
<h2 id="planning-my-approach">Planning my approach:</h2>
<ol>
<li>
<p><strong>Verification of Gene Identity</strong>: The query provides clear UniProt information (Q9H479) for human fructosamine-3-kinase. The search results consistently refer to FN3K as a fructosamine-3-kinase involved in protein deglycation. This matches the UniProt description perfectly.</p>
</li>
<li>
<p><strong>Major Themes to Cover</strong>:</p>
</li>
<li><strong>Definition and Basic Function</strong>: What is FN3K and what does it do?</li>
<li><strong>Enzymatic Mechanism</strong>: How does it catalyze protein deglycation? What is the molecular mechanism?</li>
<li><strong>Substrate Specificity</strong>: What are its specific substrates?</li>
<li><strong>Structural Architecture</strong>: What is known about its 3D structure?</li>
<li><strong>Cellular Localization</strong>: Where in the cell does it function?</li>
<li><strong>Biological Pathways and Processes</strong>: What pathways does it participate in? What is the physiological significance?</li>
<li><strong>Tissue Distribution</strong>: Where is it expressed?</li>
<li><strong>Disease Associations</strong>: Links to diabetes, cancer, and other conditions</li>
<li><strong>Genetic Variation</strong>: How do polymorphisms affect function?</li>
<li><strong>Regulatory Mechanisms</strong>: How is FN3K itself regulated (redox sensitivity, etc.)?</li>
<li><strong>Related Proteins</strong>: FN3KRP and other homologs</li>
<li>
<p><strong>Clinical and Therapeutic Implications</strong>: Potential therapeutic targeting</p>
</li>
<li>
<p><strong>Key Findings from Search Results</strong>:</p>
</li>
<li>FN3K phosphorylates fructosamines (Amadori products) on the 3' hydroxyl group [7, 13, 19, 38, 39]</li>
<li>This phosphorylation makes fructosamines unstable, leading to deglycation [2, 6, 7, 38, 39]</li>
<li>The product is 3-deoxyglucosone (3-DG) [2, 7, 13, 38, 39]</li>
</ol>
<p>The enzyme exhibits a complex cellular distribution, operating across multiple cellular compartments including the nucleus, mitochondria, and cytoplasm. Its expression profile is particularly robust in metabolically active tissues like the brain, heart, kidney, skeletal muscle, and erythrocytes. Recent structural investigations have illuminated its intricate catalytic mechanism, with a notable redox-sensitive regulation mediated through cysteine residues in the P-loop, suggesting a sophisticated molecular control system.</p>
<ul>
<li>It interacts with NRF2 and other proteins [7, 28, 31, 39]</li>
<li>FN3K has paralog FN3KRP with different substrate specificity [32, 33, 34]</li>
<li>FN3K polymorphisms affect glycation gap and diabetes complications [12, 21, 24, 26]</li>
<li>Multi-omics studies reveal interactions with metabolic enzymes (FASN, LDHA) [7, 38, 43, 49]</li>
</ul>
<p>The protein demonstrates extensive molecular interactions, engaging with transcription factor NRF2 and various cellular proteins. Its paralog FN3KRP presents distinct substrate recognition capabilities. Genetic variations in FN3K significantly impact glycation processes and contribute to diabetes-related complications. Advanced multi-omics research has uncovered intricate interactions with key metabolic enzymes like FASN and LDHA, highlighting its pivotal role in cellular metabolic networks.<br />
</think></p>
<h1 id="fructosamine-3-kinase-fn3k-structure-function-and-role-in-protein-deglycation">Fructosamine-3-Kinase (FN3K): Structure, Function, and Role in Protein Deglycation</h1>
<h2 id="executive-summary">Executive Summary</h2>
<p>Fructosamine-3-kinase (FN3K), encoded by the FN3K gene (HGNC:24822, NCBI Gene:64122) and identified by UniProt accession Q9H479 in humans, is a conserved metabolic kinase that catalyzes the removal of early glycation products from proteins through a process called deglycation[7][38][39]. This enzyme represents a critical cellular defense mechanism against protein glycation damage by phosphorylating fructosamines (Amadori products) formed through the non-enzymatic reaction of glucose with lysine residues on proteins, thereby initiating their removal and preventing the formation of toxic advanced glycation end products (AGEs)[2][7][38]. FN3K operates through a dynamic catalytic mechanism involving ATP-dependent phosphorylation of the 3-hydroxyl carbon of fructose moieties, converting unstable intermediates that rapidly decompose to harmless metabolites while regenerating the original amino acid residue[13][39]. The enzyme localizes to multiple subcellular compartments including mitochondria, nucleus, and cytoplasm[7], where it participates in metabolic regulation, redox homeostasis, and stress response pathways[38][43]. Recent discoveries have revealed FN3K's involvement in the regulation of the NRF2 transcription factor and its implications in both metabolic disorders like diabetes and malignant conditions like cancer, opening new avenues for therapeutic intervention[31][39][58].</p>
<h2 id="definition-and-primary-function">Definition and Primary Function</h2>
<h3 id="protein-glycation-and-the-deglycation-problem">Protein Glycation and the Deglycation Problem</h3>
<p>Protein glycation represents one of the most significant non-enzymatic post-translational modifications occurring in cells, resulting from the spontaneous reaction of reducing sugars such as glucose and ribose with primary amine groups on lysine and arginine residues[7][13][38][39]. This process, initiated through a Maillard reaction mechanism, begins with the formation of a reversible Schiff base intermediate that spontaneously rearranges into a more stable ketoamine (Amadori product) through a process called the Amadori rearrangement[13][14][20]. While the initial stages of protein glycation can be reversible under physiological conditions, the accumulation of glycated proteins in hyperglycemic states leads to continuous production of advanced glycation end products (AGEs) through further oxidative and degradative reactions[7][14][23]. The consequences of uncontrolled glycation include impaired protein function, aberrant protein-protein interactions, aberrant protein crosslinking with extracellular matrix components, and the generation of reactive oxygen species (ROS) that contribute to multiple chronic diseases[31][38][39]. Recognizing the deleterious effects of protein glycation, organisms have evolved enzymatic repair systems to counteract this damage, with fructosamine-3-kinase representing one of the most well-characterized and evolutionarily conserved examples of such defensive mechanisms[7][38].</p>
<h3 id="the-deglycation-mechanism-atp-dependent-phosphorylation">The Deglycation Mechanism: ATP-Dependent Phosphorylation</h3>
<p>FN3K catalyzes the phosphorylation of fructosamines formed by glycation, with the fundamental catalytic action involving the transfer of the gamma-phosphate group from adenosine triphosphate (ATP) to the 3-hydroxyl carbon of the ketosamine (fructose) moiety attached to lysine residues on proteins[2][7][13][38][39]. This phosphorylation at the 3-position triggers rapid and spontaneous decomposition of the unstable fructosamine 3-phosphate intermediate, which breaks down into inorganic phosphate and 3-deoxyglucosone (3-DG), thereby regenerating the original, non-glycated lysine residue[2][7][13][39]. The overall deglycation process catalyzed by FN3K thus represents a true protein repair mechanism, actively reversing an early but potentially harmful post-translational modification[3][6][7]. Crucially, this deglycation pathway prevents the continuous conversion of reversible Amadori products into irreversible AGE products, thereby reducing the flux through the glycation cascade that would otherwise contribute to diabetic complications and other age-related pathologies[2][12][21]. Research using FN3K knockout mice has demonstrated that when this enzyme is absent, protein-bound fructosamines accumulate significantly within cells, confirming that the FN3K-catalyzed deglycation mechanism is fully operative under physiological conditions[3][37].</p>
<h2 id="enzymatic-mechanism-and-catalytic-action">Enzymatic Mechanism and Catalytic Action</h2>
<h3 id="structural-basis-for-catalytic-activity">Structural Basis for Catalytic Activity</h3>
<p>Recent crystal structure studies published in 2024 have provided unprecedented molecular detail regarding how FN3K engages and phosphorylates its glycated substrates[9][13][39]. The human FN3K (HsFN3K) enzyme adopts a characteristic protein kinase-like (PKL) fold consisting of two major domains: an N-terminal ATP-binding lobe and a C-terminal substrate-binding lobe that together create a compact globular structure[39][46]. The ATP-binding site within the N-lobe contains conserved lysine residues, particularly Lys41, which coordinate both the alpha and beta phosphates of the bound nucleotide through direct interactions[39][46]. The substrate-binding pocket, located at the interface between the two lobes, is lined with several bulky aromatic residues including His288, Trp219, Phe252, and Tyr296, which interact with and accommodate the sugar moiety and the morpholino groups present on substrate molecules[39][46]. A critical catalytic residue, Asp217, positioned within the catalytic loop, directly interacts with the fructose sugar moiety, playing an essential role in substrate orientation and catalytic activity[39][46]. The conserved His288 residue represents a unique feature specific to the fructosamine kinase family, recognizing and interacting with the primary amine nitrogen that is analogous to the nitrogen accepting the fructose moiety during glycation[39][46].</p>
<h3 id="dynamic-substrate-binding-and-catalytic-cycling">Dynamic Substrate Binding and Catalytic Cycling</h3>
<p>Advanced structural and biochemical studies have revealed that FN3K substrate binding is highly dynamic, with significant conformational changes occurring during the catalytic cycle[39][46]. Upon ATP binding in the catalytic site, the gamma-phosphate of ATP engages in direct interactions with the sugar O2' and O3' atoms, pulling the fructose sugar moiety closer to the catalytic site and stabilizing it in a geometry favorable for phosphorylation[39][46]. The catalytic loop residue Trp219 exhibits a particularly noteworthy role as an ATP sensor, adopting different rotamer conformations depending on whether ATP or ADP is bound: when ATP is present, Trp219 flips to directly interact with the gamma-phosphate, whereas in the ADP-bound state it predominantly adopts an alternative conformation[31][39]. This ATP-sensing mechanism through Trp219 is specific to the fructosamine kinase family and represents a fundamentally different molecular mechanism from other kinase families, suggesting evolutionary optimization for this specific enzymatic function[31][39]. The sugar O3' interactions remain conserved between ATP and ADP-bound states, while additional water molecules and interactions with the catalytic Asp217 and the main chain amine of Gly152 stabilize the O4', O5', and O6' atoms in a productive geometry[31][39][46].</p>
<h3 id="phosphorylation-and-product-release">Phosphorylation and Product Release</h3>
<p>Mechanistic studies employing ultra-performance liquid chromatography coupled with mass spectrometry (UPLC-MS) have directly demonstrated FN3K-mediated deglycation through the detection of the relatively unstable fructosamine 3-phosphate intermediate by its unique mass shift of +212 daltons[13][19][39]. This direct detection confirms that FN3K catalyzes phosphorylation of the Amadori product through an ATP-dependent mechanism, supporting a sequential transfer mechanism where the gamma-phosphate is transferred from ATP to the 3-hydroxyl position of the fructose moiety[13][39]. The phosphorylated intermediate is so unstable that it undergoes rapid spontaneous decomposition, making it essentially impossible to accumulate in significant quantities under physiological conditions[13][39]. The product 3-deoxyglucosone (3-DG), which results from this decomposition, is converted to the harmless 3-deoxy-2-ketogluconic acid (DGA) through further metabolism, ensuring that the deglycation process terminates in safe, non-toxic end products[13][19][31][39].</p>
<h2 id="substrate-specificity-and-recognition">Substrate Specificity and Recognition</h2>
<h3 id="preference-for-fructoselysine-over-other-amadori-products">Preference for Fructoselysine over Other Amadori Products</h3>
<p>FN3K exhibits highly specific substrate recognition, displaying particular preference for fructose-lysine residues formed through glycation of both L and D-orientation sugars in proteins[7][38][49]. The enzyme readily phosphorylates fructoselysine (FL) residues both in free form and in accessible regions of proteins, with particularly high efficiency for fructose-epsilon-lysine formed through reaction of glucose with the lysine side chain[3][15][34][57]. Notably, FN3K distinguishes between different glycation products with remarkable selectivity: while the enzyme can also phosphorylate psicosaimes and ribulosamines under certain conditions, it does so with dramatically reduced efficiency compared to its action on fructosamines[6][11]. The substrate specificity of FN3K extends to the N-terminal alpha-amino groups found at the start of protein polypeptide chains, though with significantly reduced efficiency compared to epsilon-lysine residues, showing approximately 10-100 times lower affinity for N-terminal fructosyl amino acids compared to internal lysine residues[12][21][32]. This differential substrate specificity has important implications for hemoglobin glycation, where FN3K readily deglycates fructosamine residues at lysine positions throughout the protein but shows much less activity against the N-terminal valine of the hemoglobin beta chain where the HbA1c modification occurs[21][22][32].</p>
<h3 id="substrate-specificity-analysis-using-crystallographic-data">Substrate Specificity Analysis Using Crystallographic Data</h3>
<p>Structural studies have illuminated the molecular basis for substrate specificity through examination of the substrate-binding pocket in FN3K crystals[39][46]. The bulky aromatic residues lining the substrate-binding pocket, particularly His288, Trp219, Phe252, Tyr296, and Phe292, create a specialized binding environment that accommodates the morpholino-containing inhibitors and natural fructoselysine substrates[39][46]. His288 directly recognizes and interacts with the primary amine nitrogen of the substrate through hydrogen bonding, critical for substrate phosphorylation since mutation of His288 to phenylalanine results in significantly reduced phosphorylation activity in vitro[39][46]. The cavity created by these aromatic residues is precisely dimensioned to accommodate the fructose sugar moiety and the lysine side chain geometry, explaining why the enzyme shows such high selectivity for fructoselysine compared to other ketosamine substrates[39][46]. Interestingly, substitution of Trp219 with histidine generates a "super kinase" variant showing substantially elevated kinase activity on the commonly used synthetic substrate 1-deoxy-1-morpholinofructose (DMF) compared to wild-type FN3K, demonstrating that even modest structural modifications in this region can dramatically enhance catalytic efficiency[39][46].</p>
<h3 id="contrast-with-fn3krp-specificity">Contrast with FN3KRP Specificity</h3>
<p>While FN3K shows high selectivity for fructosamines, the related enzyme FN3K-related protein (FN3KRP) exhibits distinct substrate preferences, phosphorylating ribulosamines and erythrulosamines but not fructosamines[32][33][34][47]. This differential substrate specificity between FN3K and FN3KRP suggests evolutionary specialization, with FN3K handling early glycation products from glucose while FN3KRP addresses glycation products derived from pentose phosphates including ribose 5-phosphate and erythrose 4-phosphate[32][34][57]. The physiological substrates for FN3KRP are likely ketoamines formed from ribose-5-phosphate and erythrose-4-phosphate, which are first dephosphorylated by low-molecular-weight protein-tyrosine-phosphatase-A (LMW-PTP-A) before FN3KRP catalyzes phosphorylation at the third carbon[34][57]. This substrate specialization suggests that mammalian cells have evolved complementary deglycation systems to address glycation by different classes of reducing sugars.</p>
<h2 id="structural-architecture-and-domain-organization">Structural Architecture and Domain Organization</h2>
<h3 id="protein-kinase-like-fold-and-evolutionary-conservation">Protein Kinase-Like Fold and Evolutionary Conservation</h3>
<p>FN3K adopts a characteristic protein kinase-like (PKL) fold that places it within a broader family of kinases sharing similar overall architecture[39][46][49]. The N-terminal lobe contains the ATP-binding domain characterized by a nucleotide-binding pocket surrounded by the conserved P-loop, while the C-terminal lobe comprises the substrate-binding domain[39][46][49]. Although FN3K shares this structural similarity with eukaryotic protein kinases, structural superposition reveals significant differences in the C-terminal substrate-binding lobe, suggesting that FN3K has evolved specialized structural features optimized for recognizing and phosphorylating ketosamine substrates rather than peptide substrates typical of protein kinases[31][39]. The structural features of human FN3K (HsFN3K) bear approximately 35% sequence identity with the plant FN3K ortholog from Arabidopsis thaliana (AtFN3K), and structural superposition reveals conservation of the overall PKL-fold with an RMSD of 1.3 angstroms, indicating evolutionary conservation of the basic catalytic architecture[31][39]. Notably, FN3K shares structural similarity with bacterial putative FN3K enzymes with an RMSD of approximately 2.0 angstroms, further underscoring that HsFN3K possesses a typical kinase fold that has been conserved throughout evolution[31][39].</p>
<h3 id="p-loop-architecture-and-redox-regulation">P-loop Architecture and Redox Regulation</h3>
<p>A distinctive feature of FN3K is the presence of conserved cysteine residues in the ATP-binding P-loop that confer redox sensitivity and regulate enzyme activity through reversible disulfide bond formation[44][49]. Crystal structures of the plant ortholog AtFN3K revealed that the P-loop is stabilized in an extended conformation through an intermolecular disulfide bond connecting two chains to form a covalently-linked dimer, in which the reduction of disulfides results in enzyme activation[44][49]. Human FN3K contains an equivalent cysteine residue (C24) in the P-loop position that performs an analogous role, conferring redox sensitivity and regulating oligomerization state in response to oxidative stress[44][49]. The strained disulfides in FN3K function as redox "switches" that reversibly regulate both the activity and dimerization state of the enzyme[44][49]. In contrast, ancestral bacterial FN3K homologs lack a P-loop cysteine and consequently are not redox-sensitive, suggesting that the evolution of redox regulation in eukaryotic FN3Ks represents an adaptation to respond to cellular redox states and oxidative stress conditions[44].</p>
<h3 id="dimerization-and-oligomeric-states">Dimerization and Oligomeric States</h3>
<p>Recent structural studies have revealed that HsFN3K forms domain-swapped dimers in which the C-lobes are placed in a head-to-head orientation with the N-lobe alpha1 helix from one protomer positioned onto the N-lobe beta-sheet of the second protomer[31][39][46]. The two molecules in the asymmetric unit of HsFN3K crystals are almost identical, with an RMSD of 0.21 angstroms over 201 C-alpha atoms, suggesting stable dimeric assembly[31][39]. Notably, HsFN3K exhibits distinct dimeric assembly compared to the plant ortholog AtFN3K, with the P-loop adopting a more compact conformation in the human enzyme and packing against the N-lobe beta-sheet, resulting in reorientation of the N-lobe alpha1 helix at approximately 66 degrees[31]. This structural difference in dimerization behavior between human and plant FN3Ks suggests subfamily-specific regulatory mechanisms that may reflect adaptation to distinct cellular environments and metabolic demands[31].</p>
<h2 id="cellular-localization-and-subcellular-distribution">Cellular Localization and Subcellular Distribution</h2>
<h3 id="multiple-subcellular-compartments">Multiple Subcellular Compartments</h3>
<p>Comprehensive subcellular fractionation studies employing western blotting and immunofluorescence microscopy have revealed that HsFN3K localizes to multiple subcellular compartments including the nucleus, mitochondria, and cytoplasm in hepatic HepG2 cells[7][10]. Notably, subcellular fractionation of HepG2 cell lysates followed by immunoblotting using HsFN3K-specific antibodies revealed the presence of HsFN3K in all three compartments, with two distinct bands observed in the nuclear fraction that required validation using FN3K knockout cells to distinguish specific from non-specific signals[7]. Immunofluorescence microscopy employing co-localization analysis with TOMM20, a well-established mitochondrial marker, revealed co-localization of HsFN3K with TOMM20 evident by yellow coloration in merged images, definitively establishing the mitochondrial presence of HsFN3K[7]. The multicompartmental localization of FN3K suggests that this enzyme participates in deglycation processes occurring in distinct cellular sites, with potential roles in mitochondrial function, nuclear gene regulation, and cytoplasmic protein homeostasis[7].</p>
<h3 id="subcellular-compartmentalization-of-fn3k-family-members">Subcellular Compartmentalization of FN3K Family Members</h3>
<p>In contrast to the broad subcellular distribution of HsFN3K, the related enzyme FN3KRP exhibits more restricted subcellular localization, with immunohistochemistry studies indicating preferential localization in the nucleoplasm in different cell lines[7][49]. This compartmentalization difference between FN3K and FN3KRP suggests functional specialization, with FN3K operating across multiple cellular compartments to address glycation across diverse protein populations, while FN3KRP may be more specialized for addressing glycation of nuclear proteins or performing distinct metabolic functions in the nucleus[7][49]. The mitochondrial localization of FN3K is particularly significant, as mitochondria represent a major site of energy metabolism and reactive oxygen species production, both of which could be affected by protein glycation and potentially modulated through FN3K-catalyzed deglycation[7][38][43].</p>
<h2 id="biological-and-biochemical-pathways">Biological and Biochemical Pathways</h2>
<h3 id="integration-with-metabolic-homeostasis">Integration with Metabolic Homeostasis</h3>
<p>Comprehensive multi-omics analyses combining transcriptomics and interactomics have revealed that FN3K participates in multiple interconnected metabolic pathways extending far beyond simple protein repair[7][38][43][49]. Particularly notable is the integration of FN3K with lipid metabolism pathways, as evidenced by its strong interaction with fatty acid synthase (FASN) and the coupling of FN3K function with carbon metabolism through pyruvate metabolism and lactate dehydrogenase A (LDHA)[7][38][43][49]. Enrichment analysis of FN3K-interacting proteins revealed significant enrichment of proteins involved in glycolysis/gluconeogenesis and pyruvate metabolism, indicating that FN3K may function as a metabolic hub integrating protein repair with central carbon metabolism[7][38][49]. The association of FN3K with NAD(P)-binding proteins and its localization to mitochondria suggests potential links between FN3K and NAD-mediated energy metabolism and redox balance[7][38][43].</p>
<h3 id="nad-dependent-metabolic-connections">NAD-Dependent Metabolic Connections</h3>
<p>Recent investigations have demonstrated specific binding of HsFN3K to NAD compounds (NAD+, NADH, NADP+, NADPH) in a metal and concentration-dependent manner[7][38][43]. This NAD binding activity was revealed through thermal stability assays showing that different FN3K mutants display altered thermal stability in the presence of various NAD compounds[7][38][43]. Mutation of Phe39 to valine resulted in complete elimination of binding to NADH and NADPH while retaining detectable thermal stability for NAD+ and NADP+, along with nucleotides (AMP/ADP/ATP), suggesting selective recognition of reduced NAD compounds[7][43]. The catalytic loop residue Trp219 displayed subtle but statistically significant alterations in thermal stability between reduced and oxidized NAD compounds, with the W219A mutant showing increased stability in the presence of reduced NAD compounds (NADH/NADPH) but diminished thermal stability with oxidized forms (NAD+/NADP+)[7][43]. These findings indicate that FN3K may function as a NAD-sensitive metabolic sensor, potentially regulating protein repair activity in response to the cellular NAD redox state, which reflects the energy and biosynthetic status of the cell[7][38][43].</p>
<h3 id="deglycation-of-nrf2-and-oxidative-stress-response">Deglycation of NRF2 and Oxidative Stress Response</h3>
<p>A particularly important biological pathway involving FN3K centers on the deglycation and functional regulation of NFE2L2/NRF2, a master transcription factor controlling cellular antioxidant responses and redox homeostasis[7][28][31][39][55]. Recent work has established that FN3K specifically catalyzes site-specific phosphorylation and deglycation of multiple glycated lysine residues on NRF2 including K462, K472, K487, and arginine residues at R499, R569, and R587[31][55]. Glycation at these sites impairs NRF2 function by affecting both its protein stability and transactivation capacity, while FN3K-catalyzed deglycation reverses these inhibitory effects, thereby allowing NRF2 to maintain its transcriptional activity[31][55]. This regulatory axis between FN3K and NRF2 represents a critical intersection between protein glycation control and cellular antioxidant defense, with implications for both metabolic disorders and cancer biology[31][39][55][58].</p>
<h3 id="intracellular-deglycation-in-erythrocytes">Intracellular Deglycation in Erythrocytes</h3>
<p>FN3K exhibits particularly high activity in erythrocytes, where it functions in intracellular deglycation of hemoglobin and other cytoplasmic proteins[3][12][21][22]. Hemoglobin represents both a major glycation target in erythrocytes and a prime substrate for FN3K activity, with identified deglycation sites including Lys-alpha-16, Lys-alpha-61, Lys-alpha-139, Val-beta-1, Lys-beta-17, Lys-beta-59, Lys-beta-66, Lys-beta-132, and Lys-beta-144[22]. Some glycation sites on hemoglobin, such as Lys-alpha-139, are readily phosphorylated to maximal extent by FN3K in vitro, whereas others such as Val-beta-1 are slowly and only very partially phosphorylated, reflecting the substrate specificity and accessibility constraints encountered in the native protein structure[22]. Studies employing erythrocytes incubated with elevated glucose concentrations in the presence of 1-deoxy-1-morpholinofructose (DMF), a cell-permeable FN3K inhibitor, demonstrated substantially increased hemoglobin glycation compared to control conditions without the inhibitor, providing in vivo evidence that FN3K action significantly reduces glycation in intact cells[22].</p>
<h2 id="tissue-distribution-and-expression-patterns">Tissue Distribution and Expression Patterns</h2>
<h3 id="tissue-specific-expression-levels">Tissue-Specific Expression Levels</h3>
<p>FN3K exhibits distinctive tissue-specific expression patterns with particularly high levels in tissues susceptible to glycation-related damage and metabolic stress[15][41][49][51]. The enzyme is particularly active in brain, heart, kidney, and skeletal muscle, organs known to be vulnerable to diabetic complications and oxidative stress[15][41][49]. Expression levels are also relatively elevated in erythrocytes from humans, rats, and mice, consistent with the prominent role of FN3K in controlling hemoglobin glycation in these cells[15][41][49]. At the cellular level, HsFN3K shows high expression in the brain, kidney, liver, heart muscle, and adrenal gland based on transcriptomic analysis of human tissues, whereas HsFN3KRP expression levels are somewhat uniform throughout different tissues[49]. This differential tissue distribution between FN3K and FN3KRP suggests that FN3K has evolved specialized functions in metabolically active tissues and tissues particularly vulnerable to glycation damage, while FN3KRP may perform housekeeping functions throughout the body[49]. The particularly high expression in erythrocytes reflects the specialized requirement for controlling hemoglobin glycation in these cells, where FN3K operates in the absence of nuclei and organelles that would otherwise complicate deglycation processes[15][41].</p>
<h2 id="regulation-of-fn3k-activity">Regulation of FN3K Activity</h2>
<h3 id="redox-sensitive-regulation-through-p-loop-cysteines">Redox-Sensitive Regulation Through P-loop Cysteines</h3>
<p>FN3K activity is dynamically regulated through redox-sensitive mechanisms involving conserved cysteine residues in the ATP-binding P-loop[44][49]. In plant FN3K ortholog AtFN3K, the P-loop is stabilized in an extended conformation by a cysteine-mediated disulfide bond connecting two chains to form a covalently-linked dimer, in which reduction of the disulfide bond results in enzyme activation[44][49]. The equivalent cysteine residue is conserved in human FN3K (C24 HsFN3K), and this residue performs an analogous regulatory function, conferring redox sensitivity and regulating oligomerization state[44][49]. When proliferating cells are exposed to acute oxidative stress conditions, HsFN3K displays altered oligomerization and redox-dependent activity changes, suggesting that cellular redox state actively modulates FN3K function[44][49]. This redox regulation mechanism is physiologically relevant, as indicated by FN3K CRISPR knockout experiments in hepatocytes which revealed significant alterations in cellular redox-sensitive metabolites including glutathione and lactate[44]. The accumulation of advanced glycation end products such as 3-deoxyglucosone appears to drive conformational shifts in FN3K species toward an inactive dimeric form through oxidation of the P-loop cysteine, whereas reduced conditions maintain FN3K in an active monomeric or reduced dimeric form[44]. This creates an elegant feedback mechanism in which the products of FN3K activity can inhibit further enzyme action through oxidation-induced inactivation[44].</p>
<h3 id="genetic-polymorphisms-and-variable-activity">Genetic Polymorphisms and Variable Activity</h3>
<p>Significant inter-individual variability exists in FN3K activity within human populations, and this variability correlates with polymorphisms in the FN3K gene[12][21][24][26]. Single nucleotide polymorphisms (SNPs) in the FN3K gene alter enzyme activity, affecting glycated hemoglobin levels (HbA1c), the onset of type 2 diabetes, and pathogenic mechanisms related to diabetes complications[12][21][24][26]. Research examining erythrocyte FN3K activity in populations dichotomized for large positive or negative glycation gaps (the discrepancy between HbA1c and fructosamine measurements) revealed that individuals in the negative-GGap group showed striking threefold greater FN3K activity at any given FN3K protein level compared to the positive-GGap group[12][21][26]. This differential activity-to-concentration ratio suggests that genetic variations in the FN3K gene produce transcriptional or post-translational variants encoding products of differing specific activity[12][21][26]. The association between specific FN3K polymorphisms and differential HbA1c levels independent of average glycemia suggests that FN3K gene variants may represent important predictors of individual susceptibility to diabetes complications[12][21][26].</p>
<h2 id="related-proteins-and-family-members">Related Proteins and Family Members</h2>
<h3 id="fn3k-related-protein-fn3krp-and-subfamily-divergence">FN3K-Related Protein (FN3KRP) and Subfamily Divergence</h3>
<p>The mammalian FN3K family includes a closely related but functionally distinct enzyme designated FN3K-related protein (FN3KRP), also called ketosamine-3-kinase, which shares approximately 65% sequence identity with FN3K[34][57]. Unlike FN3K, FN3KRP does not phosphorylate fructosamines derived from glucose glycation but instead acts on ribulosamines and erythrulosamines, exhibiting specificity for ketosamines with D-orientation sugars only, whereas HsFN3K can phosphorylate ketosamines from both L and D-orientation sugars[7][33][34][49][57]. The physiological substrates for FN3KRP are likely ketoamines formed from pentose phosphates including ribose 5-phosphate and erythrose 4-phosphate[34][57]. As with FN3K, the third carbon of the ketosamine is phosphorylated by FN3KRP, leading to destabilization of the ketoamine and enabling its removal from proteins[34][57]. Experiments with intact erythrocytes indicate that FN3KRP is also a protein-repair enzyme, and the ketoamine 5- or 4-phosphates resulting from FN3KRP action are first dephosphorylated by low-molecular-weight protein-tyrosine-phosphatase-A (LMW-PTP-A) before FN3KRP catalyzes phosphorylation at the third carbon[34][57]. Interestingly, the distribution of FN3KRP in nature appears nearly universal across organisms, whereas FN3K distribution appears limited to endotherms, suggesting different evolutionary origins and biological roles for these two enzymes[32][40].</p>
<h3 id="evolutionary-conservation-across-organisms">Evolutionary Conservation Across Organisms</h3>
<p>FN3K homologs are found throughout the tree of life, present in mammals, birds, plants, and bacteria, indicating ancient evolutionary conservation of this protein repair mechanism[7][38][49]. In lower organisms, FN3K orthologs are believed to repair proteins glycated by ribose-5-phosphate, a potent glycating metabolite formed from the conserved pentose phosphate pathway[7][38][49]. The specificity of FN3K homologs present in plants and bacteria is similar to that of mammalian FN3KRP, suggesting that deglycation of ribulosamines and/or erythrulosamines represents an ancient mechanism that predates the specialization of mammalian FN3K for glucose-derived fructosamine deglycation[34][57]. Despite the remarkable conservation of FN3Ks across diverse organisms and their emerging role in protein repair, the full repertoire of biological and cellular processes linked to this important class of proteins remains incompletely understood[7][38].</p>
<h2 id="disease-associations-and-pathological-implications">Disease Associations and Pathological Implications</h2>
<h3 id="diabetes-and-glycation-gap-phenotype">Diabetes and Glycation Gap Phenotype</h3>
<p>FN3K plays a central role in controlling the accumulation of glycation products in diabetes, and variations in FN3K activity significantly influence diabetes complications independent of average blood glucose levels[12][21][26][29]. The glycation gap (GGap) phenomenon‚Äîthe discrepancy between glycated hemoglobin (HbA1c) levels and other indicators of average glycemia such as fructosamine‚Äîappears to be substantially influenced by variations in FN3K activity and expression[12][21][26][29]. Patients exhibiting a negative glycation gap (lower HbA1c relative to expected from average glycemia) show striking threefold greater FN3K activity at any given protein concentration compared to patients with positive glycation gaps[12][26][29]. This enhanced FN3K activity in negative-GGap individuals is associated with lower AGE levels (approximately 79% reduction), lower proinflammatory adipokine ratios (73% reduction in leptin-to-adiponectin ratio), and markedly lower prothrombotic PAI-1 levels (approximately 19% reduction)[12][26][29]. These findings suggest that FN3K may represent an intracellular system controlling nonenzymatic protein glycation and AGE production, providing a potential explanation for the observed inter-individual differences in diabetes complications at similar blood glucose levels[12][21][29]. The therapeutic potential of FN3K modulation is suggested by the observation that pharmacological modifications of FN3K activity may provide novel approaches to preventing diabetes complications[12][21][26].</p>
<h3 id="cancer-metabolism-and-nrf2-dependent-survival">Cancer Metabolism and NRF2-Dependent Survival</h3>
<p>Recent investigations have uncovered a critical role for FN3K in cancer cell survival through its regulation of the NRF2 transcription factor, establishing FN3K as an important oncogenic dependency in multiple cancer types[31][39][55][58]. FN3K catalyzes deglycation of NRF2 at specific glycation sites (K462, K472, K487, R499, R569, R587), and this deglycation substantially enhances NRF2 protein stability and transactivation function[31][55]. Downregulation of FN3K in liver cancer cell lines (HepG2, Huh1) and lung cancer cell lines (H3255, H460) results in impairment of NRF2 function through reduced protein stability and disrupted dimerization with small musculoaponeurotic fibrosarcoma (sMAF) proteins, all of which are critical for NRF2-dependent transcription[31][55]. Particularly compelling evidence for FN3K's role in cancer comes from studies showing that FN3K knockdown resensitizes human non-small-cell lung cancer (NSCLC) cell lines (H3255 and PC9) to erlotinib treatment, a tyrosine kinase inhibitor that is often ineffective due to NRF2-dependent survival mechanisms[31][39][55]. This resensitization effect highlights the therapeutic potential of targeting FN3K in cancer cells that exhibit survival dependency on NRF2[31][55]. The FN3K-NRF2 regulatory axis thus represents an attractive therapeutic target in multiple cancer types where NRF2 hyperactivation drives chemotherapy resistance and tumor progression[31][39][58].</p>
<h3 id="oxidative-stress-response-and-redox-homeostasis">Oxidative Stress Response and Redox Homeostasis</h3>
<p>Beyond its roles in diabetes and cancer, FN3K participates in cellular response to oxidative stress through its redox-sensitive regulation and its role in controlling NRF2-mediated antioxidant defenses[7][25][28][31][44]. The involvement of FN3K in response to oxidative stress involves mediating deglycation of NRF2, with glycation impairing NRF2 function[7][25]. FN3K CRISPR knockout experiments in hepatocytes revealed significant alterations in multiple redox-sensitive metabolites including increased glutathione and lactate levels compared to wild-type cells[44]. The increase in glutathione, a major cellular redox regulator, suggests that loss of FN3K function impairs the normal regulation of cellular redox balance[44][49]. This indicates that a regulatory mechanism of reversible P-loop oxidation in FN3K is likely operative in cells and represents an evolutionarily conserved redox-sensing mechanism[44]. The redox-sensitive regulation of FN3K through its P-loop cysteines allows the enzyme to respond dynamically to cellular oxidative stress, modulating protein repair activity in coordination with cellular redox state[44][49].</p>
<h2 id="protein-protein-interactions-and-interactome">Protein-Protein Interactions and Interactome</h2>
<h3 id="major-interaction-partners-and-metabolic-coupling">Major Interaction Partners and Metabolic Coupling</h3>
<p>Comprehensive interactomics analysis has substantially expanded the known protein-protein interaction (PPI) network of HsFN3K from just two previously documented partners to 205 potential interaction partners[7][38]. These interaction partners participate in key cellular functions in different subcellular compartments including mitochondria and nucleus[7][38]. In the cytoplasm, HsFN3K was identified as interacting with fatty acid synthase (FASN) and lactate dehydrogenase A (LDHA), key enzymes in fatty acid and pyruvate metabolism respectively[7][38][43][49]. Co-immunoprecipitation studies confirmed specific interactions between HsFN3K and both FASN and LDHA in the cytoplasmic fraction, with neither protein co-immunoprecipitating with agarose beads alone, indicating specificity of these interactions[7][38][43]. Investigation of the specificity of LDHA-HsFN3K interaction using wild-type and mutant FN3K proteins revealed that the W219A substrate-binding residue and the C24A redox-sensitive cysteine mutations both impaired HsFN3K's ability to interact with LDHA[7][43]. This suggests that these specific residues, involved in substrate binding and redox regulation respectively, are crucial for FN3K's interaction with metabolic enzymes[7][43]. The association of FN3K with these central metabolic enzymes suggests that FN3K functions as a metabolic hub coupling protein repair with central carbon and lipid metabolism[7][38][49].</p>
<h3 id="mitochondrial-and-nuclear-interacting-proteins">Mitochondrial and Nuclear Interacting Proteins</h3>
<p>FN3K's mitochondrial localization has enabled identification of numerous mitochondrial protein partners involved in energy metabolism and oxidative phosphorylation[7][38][43]. Pathway enrichment analysis revealed significant enrichment of proteins involved in oxidative phosphorylation within the inner mitochondrial membrane, emphasizing FN3K's extensive impact on mitochondrial metabolic pathways[7][43]. In the nuclear compartment, FN3K interacts with multiple proteins involved in histone deacetylation and chromatin remodeling, predominantly orchestrated by histone deacetylases (HDACs)[7][43]. The identification of enriched pathways related to protein processing in the endoplasmic reticulum, including several protein disulfide isomerases such as PDIA3, PDIA4, PDIA6, and P4HB (PDIA1), is particularly noteworthy as these enzymes catalyze isomerization of disulfides in proteins for proper folding[7][43]. This enrichment suggests functional coupling between FN3K's redox-sensitive regulation and the endoplasmic reticulum protein folding machinery[7][43].</p>
<h3 id="nad-binding-protein-enrichment">NAD-Binding Protein Enrichment</h3>
<p>Integration of transcriptomic and interactomic data revealed specific enrichment of NAD-binding proteins and NAD(P)-dependent metabolic enzymes among FN3K interaction partners[7][38][43]. This enrichment pattern, combined with FN3K's mitochondrial localization and its specific binding to NAD compounds in a metal and concentration-dependent manner, suggests potential links between FN3K function and NAD-mediated energy metabolism and redox balance[7][38][43]. The identification of metallothioneins as the most significantly enriched proteins by fold enrichment among FN3K interaction partners is particularly significant, as metallothioneins are low molecular weight (6‚Äì7 kDa) cysteine-rich proteins playing crucial roles in metal homeostasis and oxidative stress response[7][43]. The enrichment of metallothioneins among FN3K interacting proteins suggests that FN3K may coordinate with these metal-binding proteins to regulate cellular redox homeostasis and respond to oxidative stress conditions[7][43].</p>
<h2 id="genetic-variation-and-therapeutic-targeting">Genetic Variation and Therapeutic Targeting</h2>
<h3 id="pharmacological-inhibition-and-drug-development">Pharmacological Inhibition and Drug Development</h3>
<p>The emerging recognition of FN3K's critical roles in diabetes complications, cancer progression, and metabolic disorders has prompted significant interest in developing specific FN3K inhibitors as therapeutic agents[30][58]. In silico screening of anticancer molecules and protein kinase inhibitors has identified potential compounds capable of modulating FN3K activity through molecular docking to the catalytic domain in the three-dimensional structure of human FN3K designed through homology modeling[30]. The synthetic FN3K inhibitor 1-deoxy-1-morpholinofructose (DMF), a cell-permeable competitive inhibitor of FN3K, has been extensively used in research to demonstrate FN3K's physiological roles, with studies showing that DMF treatment can inhibit approximately 10% of total FN3K activity in red blood cell lysates[30]. Treatment of normal and diabetic rats with FN3K inhibitors demonstrated a large reduction (approximately 50%) in systemic 3-deoxyglucosone in both groups, suggesting that removal of 3-DG at its source by FN3K inhibition represents a viable option for treating diabetes-related diseases requiring much smaller drug doses compared to strategies targeting downstream AGE formation[2].</p>
<h3 id="structural-basis-for-selective-inhibitor-design">Structural Basis for Selective Inhibitor Design</h3>
<p>The recent crystal structures of human FN3K have provided crucial insights for rational small-molecule inhibitor design targeting specific residues critical for FN3K function[9][13][31][39][46]. The catalytic loop residue Trp219 represents a particularly promising therapeutic target, as this residue is specific to the fructosamine kinase family and is responsible for ATP sensing through its unique rotamer conformations[31][39]. Targeting Trp219 might provide a specific handle to selectively regulate FN3K-mediated phosphorylation in cancer cells and other pathological conditions without affecting other kinase families[31][39]. Similarly, the substrate-binding residue His288, which is critical for FN3K substrate phosphorylation, could represent another selective inhibitor target, as mutation of His288 to phenylalanine substantially reduces kinase activity on the DMF substrate[39][46]. The characterization of FN3K's specific ATP-sensing mechanism, which differs fundamentally from other kinases, provides an additional avenue for developing highly selective FN3K inhibitors that would not cross-react with standard kinase inhibitors used in other therapeutic contexts[31][39].</p>
<h3 id="potential-therapeutic-applications-in-cancer">Potential Therapeutic Applications in Cancer</h3>
<p>FN3K inhibition represents a particularly promising therapeutic strategy in cancers dependent on NRF2-driven antioxidant defenses, particularly non-small-cell lung cancer and hepatocellular carcinoma where NRF2 hyperactivation is prevalent[31][39][55][58]. The discovery that FN3K knockdown resensitizes NSCLC cell lines to erlotinib suggests that combination therapies pairing FN3K inhibitors with conventional tyrosine kinase inhibitors could overcome chemotherapy resistance driven by NRF2-dependent survival mechanisms[31][55]. The potential synergistic effect of combining FN3K inhibitors with conventional anticancer agents is supported by evidence that multiple cancer types exhibit elevated FN3K expression associated with poor prognosis and treatment resistance[31][58]. Furthermore, the multi-omics evidence of FN3K's coupling to metabolic pathways including fatty acid and pyruvate metabolism suggests that FN3K inhibition might not only impair antioxidant defenses but also disrupt cancer cell metabolism, providing additional therapeutic benefit[7][38][49].</p>
<h3 id="therapeutic-applications-in-diabetes-and-glycation-related-diseases">Therapeutic Applications in Diabetes and Glycation-Related Diseases</h3>
<p>In the context of diabetes therapy, FN3K modulation represents a fundamentally different approach compared to conventional glucose-lowering strategies, as it targets the accumulation of glycation products rather than glucose levels directly[2][12][21][26]. The observation that FN3K inhibition produces a large reduction in systemic 3-deoxyglucosone, a key glycation-derived oxidative stress marker, suggests that blocking FN3K-mediated production of 3-DG might reduce oxidative stress and inflammatory responses contributing to diabetic complications[2]. However, the complex role of FN3K in both protein repair and the generation of 3-DG requires careful consideration: while inhibition reduces 3-DG production, it simultaneously impairs deglycation and potentially increases protein glycation accumulation[2][12][21]. Future therapeutic strategies might thus involve pharmacological agents that enhance FN3K activity or expression rather than inhibiting it, particularly in individuals carrying loss-of-function polymorphisms[12][21][26]. The association between FN3K activity and the glycation gap phenotype, with implications for cardiovascular outcomes and mortality in diabetic patients, suggests that FN3K-modulating therapeutics could provide personalized approaches to diabetes complication prevention[12][21][26].</p>
<h2 id="conclusion">Conclusion</h2>
<p>Fructosamine-3-kinase represents an evolutionarily ancient and remarkably conserved protein repair enzyme that addresses a fundamental threat to cellular homeostasis posed by non-enzymatic protein glycation. Through ATP-dependent phosphorylation of Amadori products on lysine residues, FN3K catalyzes the removal of early glycation products before they irreversibly convert to toxic advanced glycation end products, thereby functioning as a critical cellular defense mechanism against glucose toxicity. The recent determination of human FN3K crystal structures has illuminated the molecular basis for its catalytic activity, substrate recognition, and regulation, revealing unique structural features including an ATP-sensing mechanism specific to the fructosamine kinase family and redox-sensitive cysteines that modulate enzyme activity in response to cellular oxidative stress. The multicompartmental localization of FN3K across nucleus, mitochondria, and cytoplasm enables this enzyme to address glycation damage across diverse protein populations and cellular sites. The comprehensive protein-protein interaction network identified through multi-omics studies reveals FN3K as a metabolic hub coupling protein repair with central carbon and lipid metabolism, energy production, and redox homeostasis. Inter-individual variations in FN3K activity driven by genetic polymorphisms substantially influence individual susceptibility to diabetes complications, as evidenced by the strong association between FN3K activity and the glycation gap phenotype. The recently discovered role of FN3K in deglycation and regulation of NRF2 has opened entirely new therapeutic avenues in cancer biology, where FN3K inhibition could resensitize treatment-resistant tumors to conventional therapies. As our understanding of FN3K's biology expands and sophisticated structural tools enable rational design of selective inhibitors, FN3K emerges as a compelling therapeutic target in both metabolic disorders and malignancy. Future therapeutic development must carefully balance the opposing effects of FN3K modulation‚Äîenhanced deglycation versus increased 3-deoxyglucosone production‚Äîwhile leveraging structure-based inhibitor design to achieve selectivity and minimize off-target effects. The evolutionary conservation of FN3K across organisms and its fundamental role in maintaining protein homeostasis under glycation stress underscore this enzyme's importance for understanding both aging processes and age-associated diseases, positioning FN3K research at the nexus of metabolism, redox biology, and disease prevention.</p>
<h2 id="citations">Citations</h2>
<ol>
<li>https://www.ncbi.nlm.nih.gov/gene?Db=gene&amp;Cmd=DetailsSearch&amp;Term=64122</li>
<li>https://en.wikipedia.org/wiki/Fructosamine-3-kinase</li>
<li>https://pubmed.ncbi.nlm.nih.gov/16819943/</li>
<li>https://www.uniprot.org/uniprotkb/Q9H479/entry</li>
<li>https://www.ncbi.nlm.nih.gov/gene/64122</li>
<li>https://pubmed.ncbi.nlm.nih.gov/14633848/</li>
<li>https://www.nature.com/articles/s41540-024-00390-0</li>
<li>https://pubmed.ncbi.nlm.nih.gov/11522682/</li>
<li>https://pubmed.ncbi.nlm.nih.gov/39173621/</li>
<li>https://www.genecards.org/cgi-bin/carddisp.pl?gene=FN3K</li>
<li>https://diabetesjournals.org/diabetes/article/50/9/2139/11062/Human-Fructosamine-3-KinasePurification-Sequencing</li>
<li>https://diabetesjournals.org/diabetes/article/67/1/131/15826/Evidence-That-Differences-in-Fructosamine-3-Kinase</li>
<li>https://www.nature.com/articles/s41467-025-56207-z</li>
<li>https://en.wikipedia.org/wiki/Fructosamine</li>
<li>https://pubmed.ncbi.nlm.nih.gov/15331600/</li>
<li>https://diabetesjournals.org/diabetes/article-abstract/50/9/2139/11062</li>
<li>https://www.proteinatlas.org/ENSG00000167363-FN3K</li>
<li>https://home.sandiego.edu/~josephprovost/Maillard%20Reaction%20Proofs.pdf</li>
<li>https://pubmed.ncbi.nlm.nih.gov/15102834/</li>
<li>https://pubs.acs.org/doi/10.1021/acs.jafc.7b00882</li>
<li>https://pubmed.ncbi.nlm.nih.gov/16523184/</li>
<li>https://www.uniprot.org/uniprotkb/Q9ER35/entry</li>
<li>https://pubmed.ncbi.nlm.nih.gov/29066600/</li>
<li>https://portlandpress.com/biochemj/article/416/2/281/44594/Mapping-of-the-ATP-binding-domain-of-human</li>
<li>https://www.nature.com/articles/s41420-025-02491-z</li>
<li>https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0283705</li>
<li>https://www.liebertpub.com/doi/10.1089/rej.2021.0009</li>
<li>https://maayanlab.cloud/Harmonizome/gene/FN3KRP</li>
<li>https://pubmed.ncbi.nlm.nih.gov/20967558/</li>
<li>https://portlandpress.com/biochemj/article/365/3/801/40186/Fructosamine-3-kinase-is-involved-in-an</li>
<li>https://www.uniprot.org/uniprotkb/Q9HA64/entry</li>
<li>https://pubmed.ncbi.nlm.nih.gov/34314247/</li>
<li>https://www.science.org/doi/10.1126/scisignal.aax6313</li>
<li>https://diabetesjournals.org/diabetes/article/74/7/1289/158067/Are-Polymorphisms-Within-the-Fructosamine-3-Kinase</li>
<li>https://diabetesjournals.org/diabetes/article/52/12/2888/11115/A-Mammalian-Protein-Homologous-to-Fructosamine-3</li>
<li>https://pubmed.ncbi.nlm.nih.gov/15381090/</li>
<li>https://accscience.com/journal/EJMO/8/4/10.14744/ejmo.2024.20665</li>
<li>https://repository.cshl.edu/id/eprint/41635/1/10.1101.2024.08.05.606604.pdf</li>
</ol>
            </div>
        </details>
        
        <details class="markdown-section">
            <summary style="display: flex; justify-content: space-between; align-items: center; cursor: pointer;">
                <div style="flex: 1;">
                    <h3 style="display: inline;">Notes</h3>
                    <span style="font-size: 0.8rem; color: #666; margin-left: 1rem;">(FN3K-notes.md)</span>
                </div>
                <div class="vote-buttons" data-g="Q9H479" data-a="DOC: Notes" data-r="" data-act="DOCUMENTATION" style="display: flex; gap: 0.25rem;">
                    <button class="vote-btn" data-v="up" title="This documentation is helpful">üëç</button>
                    <button class="vote-btn" data-v="down" title="This documentation needs improvement">üëé</button>
                </div>
            </summary>
            <div class="markdown-content">
                <h1 id="fn3k-gene-review-notes">FN3K Gene Review Notes</h1>
<h2 id="overview">Overview</h2>
<p>FN3K (Fructosamine-3-kinase) is a protein repair enzyme that reverses non-enzymatic glycation of proteins. It phosphorylates the 3-position of fructosamine residues on glycated proteins, creating an unstable intermediate that spontaneously decomposes to regenerate the original lysine residue.</p>
<hr />
<h2 id="reference-summaries-with-key-excerpts">Reference Summaries with Key Excerpts</h2>
<h3 id="pmid11016445-delpierre-et-al-2000-discovery-paper">PMID:11016445 - Delpierre et al., 2000 (Discovery Paper)</h3>
<p><strong>Title:</strong> Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase</p>
<p><strong>Key Findings:</strong></p>
<ol>
<li><strong>Enzyme identification and purification:</strong></li>
<li>
<p>"The enzyme responsible for this conversion was purified approximately 2,500-fold by chromatography on Blue Sepharose, Q Sepharose, and Sephacryl S-200 and shown to copurify with a 35,000-M(r) protein."</p>
</li>
<li>
<p><strong>Substrate specificity (ranked by affinity):</strong></p>
</li>
<li>"They were shown to catalyze the phosphorylation of DMF, fructoselysine, fructoseglycine, and fructose in order of decreasing affinity."</li>
<li>
<p>Also phosphorylates glycated proteins: "They also phosphorylated glycated lysozyme, though not unmodified lysozyme."</p>
</li>
<li>
<p><strong>Site of phosphorylation:</strong></p>
</li>
<li>
<p>"Nuclear magnetic resonance analysis of phosphorylated DMF and phosphorylated fructoseglycine showed that the phosphate was bound to the third carbon of the 1-deoxyfructose moiety."</p>
</li>
<li>
<p><strong>Proposed function:</strong></p>
</li>
<li>"The physiological function of fructosamine-3-kinase may be to initiate a process leading to the deglycation of fructoselysine and of glycated proteins."</li>
</ol>
<hr />
<h3 id="pmid11522682-szwergold-et-al-2001">PMID:11522682 - Szwergold et al., 2001</h3>
<p><strong>Title:</strong> Human fructosamine-3-kinase: purification, sequencing, substrate specificity, and evidence of activity in vivo</p>
<p><strong>Key Findings:</strong></p>
<ol>
<li><strong>Mechanism of deglycation:</strong></li>
<li>
<p>"FN3K... phosphorylates fructoselysine (FL) residues on glycated proteins, to generate fructoselysine-3 phosphate (FL3P). This phosphorylation destabilizes the FL adduct and leads to its spontaneous decomposition, thereby reversing the nonenzymatic glycation process at an early stage."</p>
</li>
<li>
<p><strong>Protein characteristics:</strong></p>
</li>
<li>"The protein thus identified is a 35-kDa monomer that appears to be expressed in all mammalian tissues."</li>
<li>"It has no significant homology to other known proteins"</li>
<li>
<p>Located on "human chromosomes 1 and 17"</p>
</li>
<li>
<p><strong>Biological importance:</strong></p>
</li>
<li>"Because the condensation of glucose and lysine residues is an ubiquitous and unavoidable process in homeothermic organisms, a deglycation system mediated by FN3K may be an important factor in protecting cells from the deleterious effects of nonenzymatic glycation."</li>
</ol>
<hr />
<h3 id="pmid11975663-delpierre-et-al-2002">PMID:11975663 - Delpierre et al., 2002</h3>
<p><strong>Title:</strong> Fructosamine 3-kinase is involved in an intracellular deglycation pathway in human erythrocytes</p>
<p><strong>Key Findings:</strong></p>
<ol>
<li><strong>Direct evidence of in vivo activity:</strong></li>
<li>"incubation of human erythrocytes with 200 mM glucose not only caused the progressive formation of glycated haemoglobin, but also increased the level of an anionic form of haemoglobin containing alkali-labile phosphate"</li>
<li>
<p>The phosphorylated intermediate reaches "approx. 5% of total haemoglobin"</p>
</li>
<li>
<p><strong>DMF inhibition experiments (proving FN3K involvement):</strong></p>
</li>
<li>
<p>"1-Deoxy-1-morpholinofructose (DMF), a substrate and competitive inhibitor of fructosamine 3-kinase, doubled the rate of accumulation of glycated haemoglobin, but markedly decreased the amount of haemoglobin containing alkali-labile phosphate."</p>
</li>
<li>
<p><strong>Deglycation cycle demonstrated:</strong></p>
</li>
<li>
<p>"Returning erythrocytes incubated with 200 mM glucose and DMF to a low-glucose medium devoid of DMF caused a decrease in the amount of glycated haemoglobin, a transient increase in FN3P-Hb and a net decrease in the sum (glycated haemoglobin+FN3P-Hb)."</p>
</li>
<li>
<p><strong>Product identification:</strong></p>
</li>
<li>"The second step of this 'deglycation' process is most likely a spontaneous decomposition of the fructosamine 3-phosphate residues to a free amine, 3-deoxyglucosone and P(i)."</li>
<li>"2-oxo-3-deoxygluconate, the product of 3-deoxyglucosone oxidation, is formed in erythrocytes"</li>
</ol>
<hr />
<h3 id="pmid21492153-buhrke-et-al-2011">PMID:21492153 - Buhrke et al., 2011</h3>
<p><strong>Title:</strong> Analysis of proteomic changes induced upon cellular differentiation of the human intestinal cell line Caco-2</p>
<p><strong>Key Findings:</strong></p>
<p>This is a <strong>high-throughput proteomics study</strong> of Caco-2 cell differentiation. FN3K was one of 34 proteins identified as differentially regulated during differentiation.</p>
<p><strong>Relevance to FN3K annotation:</strong><br />
- FN3K was detected as differentially expressed during epithelial differentiation<br />
- This provides expression-based evidence (IEP) but does NOT demonstrate a direct functional role in epithelial differentiation<br />
- The annotation GO:0030855 "epithelial cell differentiation" based on this study is <strong>weak</strong> - it's correlation, not causation</p>
<hr />
<h3 id="reactomer-hsa-163841-gamma-carboxylation-hypusinylation-hydroxylation-and-arylsulfatase-activation">Reactome:R-HSA-163841 - Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation</h3>
<p><strong>Summary:</strong> "After translation, many newly formed proteins undergo further covalent modifications that alter their functional properties... These modifications include the vitamin K-dependent attachment of carboxyl groups to glutamate residues and the conversion of a lysine residue in eIF5A to hypusine..."</p>
<p><strong>Assessment:</strong> This pathway annotation for FN3K seems <strong>misplaced</strong>. The pathway describes irreversible PTMs (gamma-carboxylation, hypusinylation, hydroxylation), but FN3K is involved in <strong>reversing</strong> glycation (a different type of modification). The connection is tenuous - both involve protein modification, but the biological context differs.</p>
<hr />
<h3 id="reactomer-hsa-6788867-fn3k-phosphorylates-ketosamines">Reactome:R-HSA-6788867 - FN3K phosphorylates ketosamines</h3>
<p><strong>Summary:</strong> "Ketosamine-3-kinase (FN3K) and ketosamine-3-kinase-related protein (FN3KRP) can phosphorylate protein-bound or free ketosamines on the third carbon of the sugar moiety and the resultant, unstable ketosamine 3-phosphates decompose under physiological conditions (a process called deglycation)."</p>
<p><strong>Key distinction:</strong><br />
- "Both enzymes can 3-phosphorylate psicosamines (PsiAm) and ribulosamines (RibAm), but <strong>only FN3K can 3-phosphorylate fructosamines (FruAm)</strong> as well"</p>
<p><strong>Assessment:</strong> This is the appropriate Reactome pathway for FN3K function.</p>
<hr />
<h2 id="uniprot-record-summary-q9h479">UniProt Record Summary (Q9H479)</h2>
<h3 id="enzyme-classification">Enzyme Classification</h3>
<ul>
<li><strong>EC 2.7.1.171</strong> - protein-fructosamine 3-kinase (primary activity)</li>
<li><strong>EC 2.7.1.172</strong> - protein-ribulosamine 3-kinase (secondary activity)</li>
<li>Also phosphorylates psicosamines</li>
</ul>
<h3 id="catalytic-activities-from-uniprot">Catalytic Activities (from UniProt)</h3>
<ol>
<li>
<p><strong>Fructosamine phosphorylation:</strong><br />
<code>N(6)-(D-fructosyl)-L-lysyl-[protein] + ATP ‚Üí
   N(6)-(3-O-phospho-D-fructosyl)-L-lysyl-[protein] + ADP + H(+)</code></p>
</li>
<li>
<p><strong>Ribulosamine phosphorylation:</strong><br />
<code>N(6)-D-ribulosyl-L-lysyl-[protein] + ATP ‚Üí
   N(6)-(3-O-phospho-D-ribulosyl)-L-lysyl-[protein] + ADP + H(+)</code></p>
</li>
<li>
<p><strong>Psicosamine phosphorylation:</strong><br />
<code>N(6)-(D-psicosyl)-L-lysyl-[protein] + ATP ‚Üí
   N(6)-(3-O-phospho-D-psicosyl)-L-lysyl-[protein] + ADP + H(+)</code></p>
</li>
</ol>
<h3 id="kinetic-parameters-pmid14633848">Kinetic Parameters (PMID:14633848)</h3>
<table>
<thead>
<tr>
<th>Substrate</th>
<th>KM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deoxymorpholinofructose</td>
<td>10 ¬µM</td>
</tr>
<tr>
<td>Deoxymorpholinoribulose</td>
<td>2.6 ¬µM</td>
</tr>
<tr>
<td>Psicoselysine</td>
<td>140 ¬µM</td>
</tr>
<tr>
<td>Deoxymorpholinopsicose</td>
<td>160 ¬µM</td>
</tr>
</tbody>
</table>
<h3 id="key-structural-features">Key Structural Features</h3>
<ul>
<li><strong>309 amino acids</strong>, 35 kDa monomer</li>
<li><strong>Active site:</strong> D217 (proton acceptor)</li>
<li><strong>ATP binding:</strong> residues 89-91</li>
<li><strong>N-terminal modification:</strong> N-acetylmethionine at position 1</li>
<li><strong>Crystal structures available:</strong> PDB 8UE1, 9CX8, 9CXM, 9CXN, 9CXO, 9CXV, 9CXW</li>
</ul>
<h3 id="expression">Expression</h3>
<ul>
<li>Widely expressed (all mammalian tissues)</li>
<li>Particularly active in erythrocytes</li>
<li>Also localized to mitochondria (IDA evidence)</li>
</ul>
<h3 id="additional-function-by-similarity">Additional Function (by similarity)</h3>
<ul>
<li>"Involved in the response to oxidative stress by mediating deglycation of NFE2L2/NRF2, glycation impairing NFE2L2/NRF2 function"</li>
</ul>
<hr />
<h2 id="notes-on-existing-go-annotations">Notes on Existing GO Annotations</h2>
<h3 id="annotations-that-appear-sound">Annotations that appear SOUND:</h3>
<ul>
<li><strong>GO:0102194</strong> protein-fructosamine 3-kinase activity - This is the core molecular function</li>
<li><strong>GO:0036525</strong> protein deglycation - This is the core biological process</li>
<li><strong>GO:0005524</strong> ATP binding - Required for kinase activity</li>
<li><strong>GO:0016301</strong> kinase activity - Correct but too general</li>
<li><strong>GO:0005829</strong> cytosol - Reasonable localization</li>
<li><strong>GO:0005739</strong> mitochondrion - Has IDA evidence from HPA</li>
</ul>
<h3 id="annotations-that-are-questionable">Annotations that are QUESTIONABLE:</h3>
<ul>
<li><strong>GO:0030855</strong> epithelial cell differentiation (IEP) - Based on expression correlation in Caco-2 proteomics study. Does not indicate direct functional role.</li>
<li><strong>GO:0043687</strong> post-translational protein modification (Reactome:R-HSA-163841) - Pathway connection is weak/inappropriate</li>
<li><strong>GO:0102193</strong> protein-ribulosamine 3-kinase activity - FN3K CAN do this (PMID:14633848), but it's not the primary activity. The paralog FN3KRP is the main ribulosamine kinase.</li>
</ul>
<h3 id="annotations-with-redundancy">Annotations with REDUNDANCY:</h3>
<ul>
<li>Multiple annotations to GO:0016301 (kinase activity) from different sources</li>
<li>Multiple annotations to GO:0102194 from different evidence types</li>
<li>GO:0000166 (nucleotide binding) vs GO:0005524 (ATP binding) - ATP binding is more specific</li>
<li>GO:0016740 (transferase activity) vs GO:0016301 (kinase activity) - kinase is more specific</li>
</ul>
<hr />
<h2 id="deep-research-additional-insights">Deep Research Additional Insights</h2>
<p>From the deep research files (perplexity and falcon), additional key points:</p>
<h3 id="substrate-specificity-details">Substrate Specificity Details</h3>
<ul>
<li>FN3K has 10-100x higher affinity for Œµ-lysine fructosamines vs N-terminal modifications</li>
<li>This explains limited effect on HbA1c (glycated at N-terminal valine of Hb Œ≤-chain)</li>
<li>FN3K handles glucose-derived fructosamines; FN3KRP handles pentose-derived ketosamines</li>
</ul>
<h3 id="regulation">Regulation</h3>
<ul>
<li>Redox-sensitive via P-loop cysteine (C24 in human)</li>
<li>Forms disulfide-linked dimers in oxidized state (less active)</li>
<li>Reduced state is more active (monomeric or reduced dimer)</li>
</ul>
<h3 id="protein-interactions">Protein Interactions</h3>
<ul>
<li>NAD/NADH binding capability (metal and concentration dependent)</li>
<li>Interacts with FASN, LDHA in cytoplasm</li>
<li>Role in NRF2 deglycation affecting oxidative stress response</li>
</ul>
<h3 id="localization">Localization</h3>
<ul>
<li>Multi-compartmental: cytosol, mitochondria, nucleus</li>
<li>High activity in erythrocytes (confirmed by multiple studies)</li>
</ul>
<hr />
<h2 id="questionsissues-to-resolve">Questions/Issues to Resolve</h2>
<ol>
<li>
<p>Should GO:0030855 (epithelial cell differentiation) be removed? The evidence is weak (expression correlation only).</p>
</li>
<li>
<p>The Reactome pathway R-HSA-163841 seems inappropriate - should the TAS annotation to GO:0043687 be reviewed?</p>
</li>
<li>
<p>Is GO:0102193 (protein-ribulosamine 3-kinase activity) appropriate for FN3K, or should it only be annotated to FN3KRP?</p>
</li>
<li>
<p>Should more specific process terms be considered, such as:</p>
</li>
<li>Protein repair?</li>
<li>Response to oxidative stress?</li>
<li>Advanced glycation end-product metabolic process?</li>
</ol>
<hr />
<p><em>Notes compiled: 2024-12-04</em></p>
            </div>
        </details>
        
    </div>
    

    <!-- YAML Preview Section -->
    <div class="section">
        <details class="yaml-preview">
            <summary>
                <h2 style="display: inline;">üìÑ View Raw YAML</h2>
            </summary>
            <div class="yaml-content">
                <pre><code>id: Q9H479
gene_symbol: FN3K
product_type: PROTEIN
status: DRAFT
taxon:
  id: NCBITaxon:9606
  label: Homo sapiens
description: &gt;-
  Fructosamine-3-kinase (FN3K) is a protein repair enzyme that catalyzes the ATP-dependent
  phosphorylation of fructosamines (Amadori products) on glycated proteins at the 3-position
  of the sugar moiety. This phosphorylation creates an unstable intermediate (fructosamine
  3-phosphate) that spontaneously decomposes to release 3-deoxyglucosone, inorganic phosphate,
  and the regenerated free lysine residue, thereby reversing non-enzymatic glycation. FN3K
  is widely expressed but particularly active in erythrocytes where it participates in
  hemoglobin deglycation. The enzyme can also phosphorylate psicosamines and ribulosamines
  with lower efficiency. FN3K activity is redox-regulated through a P-loop cysteine residue.
existing_annotations:
- term:
    id: GO:0016301
    label: kinase activity
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: &gt;-
      Correct but too general. FN3K has specific fructosamine 3-kinase activity (GO:0102194)
      which is more informative. The generic kinase activity annotation is redundant given
      that more specific MF annotations exist.
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0030389
    label: fructosamine metabolic process
  evidence_type: IBA
  original_reference_id: GO_REF:0000033
  review:
    summary: &gt;-
      Appropriate BP annotation. FN3K is involved in fructosamine metabolism by phosphorylating
      fructosamines to initiate their removal from proteins. This is a core function.
    action: ACCEPT
- term:
    id: GO:0000166
    label: nucleotide binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: &gt;-
      Redundant with more specific ATP binding annotation (GO:0005524). Should be
      removed in favor of the more specific term.
    action: MODIFY
    proposed_replacement_terms:
    - id: GO:0005524
      label: ATP binding
- term:
    id: GO:0005524
    label: ATP binding
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: &gt;-
      Correct. FN3K uses ATP as phosphate donor for its kinase activity. Kinetic data
      confirms ATP binding. UniProt documents ATP binding site at residues 89-91.
    action: ACCEPT
- term:
    id: GO:0016301
    label: kinase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: &gt;-
      Duplicate of IBA annotation to same term. Correct but too general - the specific
      protein-fructosamine 3-kinase activity (GO:0102194) should be preferred.
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0016740
    label: transferase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000043
  review:
    summary: &gt;-
      Too general. This is a high-level parent term of kinase activity. Not informative
      when more specific annotations exist.
    action: REMOVE
- term:
    id: GO:0102193
    label: protein-ribulosamine 3-kinase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: &gt;-
      FN3K can phosphorylate ribulosamines (PMID:14633848) but with lower affinity than
      fructosamines. The KM for deoxymorpholinoribulose is 2.6 uM vs 10 uM for DMF.
      However, the primary physiological substrate is fructosamines from glucose glycation.
      FN3KRP is the dedicated ribulosamine kinase. This annotation is technically correct
      but represents a secondary activity.
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0102194
    label: protein-fructosamine 3-kinase activity
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: &gt;-
      Core molecular function. FN3K specifically phosphorylates fructoselysine residues
      on glycated proteins at the 3-position, generating fructosamine 3-phosphate. This
      is the defining enzymatic activity of FN3K (EC 2.7.1.171).
    action: ACCEPT
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: IEA
  original_reference_id: GO_REF:0000120
  review:
    summary: &gt;-
      Correct. FN3K is present in the cytosol where it can act on cytoplasmic glycated
      proteins. Evidence from multiple studies supports cytosolic localization.
    action: ACCEPT
- term:
    id: GO:0043687
    label: post-translational protein modification
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-163841
  review:
    summary: &gt;-
      Questionable pathway assignment. R-HSA-163841 covers gamma carboxylation, hypusinylation,
      hydroxylation - irreversible PTMs. FN3K is involved in REMOVING glycation (deglycation),
      not adding PTMs. The phosphorylation FN3K performs on glycated substrates is transient
      and part of a repair process, not a stable modification. This annotation may be
      misleading about FN3K&#39;s actual function.
    action: MARK_AS_OVER_ANNOTATED
- term:
    id: GO:0005739
    label: mitochondrion
  evidence_type: IDA
  original_reference_id: GO_REF:0000052
  review:
    summary: &gt;-
      Supported by IDA evidence (HPA immunofluorescence data). Multi-omics studies also
      confirm mitochondrial localization and interaction with mitochondrial proteins.
      FN3K may deglycate mitochondrial proteins.
    action: ACCEPT
- term:
    id: GO:0016301
    label: kinase activity
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6788867
  review:
    summary: &gt;-
      Third annotation to the same generic term. Correct but too general - the specific
      protein-fructosamine 3-kinase activity (GO:0102194) should be preferred. Keeping
      consistent with other kinase activity annotations.
    action: KEEP_AS_NON_CORE
- term:
    id: GO:0036525
    label: protein deglycation
  evidence_type: IDA
  original_reference_id: PMID:11522682
  review:
    summary: &gt;-
      Core biological process. PMID:11522682 (Szwergold et al.) directly demonstrated
      that FN3K phosphorylation of fructoselysine destabilizes the adduct, leading to
      spontaneous decomposition and reversal of glycation. This is the primary biological
      function of FN3K.
    action: ACCEPT
    supported_by:
    - reference_id: file:human/FN3K/FN3K-deep-research-perplexity.md
      supporting_text: &gt;-
        FN3K&#39;s enzymatic phosphorylation at the C3 position creates an unstable
        fructosamine-3-phosphate intermediate that spontaneously decomposes
- term:
    id: GO:0036525
    label: protein deglycation
  evidence_type: IDA
  original_reference_id: PMID:11975663
  review:
    summary: &gt;-
      Same term as above with additional supporting evidence. PMID:11975663 (Delpierre et al.)
      provided in vivo evidence in erythrocytes showing FN3K mediates intracellular
      deglycation of hemoglobin. DMF inhibitor experiments proved FN3K involvement in
      removing fructosamine residues. Strong supporting evidence for this core function.
    action: ACCEPT
- term:
    id: GO:0102194
    label: protein-fructosamine 3-kinase activity
  evidence_type: IDA
  original_reference_id: PMID:11016445
  review:
    summary: &gt;-
      Core molecular function with strong experimental evidence. The discovery paper
      demonstrated FN3K phosphorylates fructosamines at the third carbon position via
      NMR analysis of products. Substrates tested included DMF, fructoselysine,
      fructoseglycine, and glycated lysozyme.
    action: ACCEPT
- term:
    id: GO:0102194
    label: protein-fructosamine 3-kinase activity
  evidence_type: IDA
  original_reference_id: PMID:11522682
  review:
    summary: &gt;-
      Duplicate annotation to same term with additional supporting evidence. PMID:11522682
      confirmed substrate specificity and characterized the enzyme. Supports core MF.
    action: ACCEPT
- term:
    id: GO:0102194
    label: protein-fructosamine 3-kinase activity
  evidence_type: IDA
  original_reference_id: PMID:11975663
  review:
    summary: &gt;-
      Third IDA annotation to same term. Evidence from in vivo erythrocyte studies
      confirming FN3K activity on hemoglobin fructosamines.
    action: ACCEPT
- term:
    id: GO:0005829
    label: cytosol
  evidence_type: TAS
  original_reference_id: Reactome:R-HSA-6788867
  review:
    summary: &gt;-
      Duplicate cytosol annotation from Reactome pathway. Consistent with other evidence
      supporting cytosolic localization.
    action: ACCEPT
- term:
    id: GO:0030855
    label: epithelial cell differentiation
  evidence_type: IEP
  original_reference_id: PMID:21492153
  review:
    summary: &gt;-
      Weak evidence. PMID:21492153 is a proteomics study of Caco-2 cell differentiation
      where FN3K was identified as one of 34 differentially expressed proteins. This
      shows expression correlation, not functional involvement in differentiation.
      FN3K&#39;s deglycation activity has no mechanistic connection to epithelial differentiation.
      This appears to be an over-interpretation of high-throughput expression data.
    action: REMOVE
- term:
    id: GO:0030393
    label: fructoselysine metabolic process
  evidence_type: NAS
  original_reference_id: PMID:11016445
  review:
    summary: &gt;-
      Appropriate annotation. FN3K phosphorylates fructoselysine (protein-bound and free)
      as a primary substrate. The discovery paper demonstrated high affinity for
      fructoselysine. This is more specific than GO:0030389 (fructosamine metabolic process).
    action: ACCEPT
- term:
    id: GO:0102194
    label: protein-fructosamine 3-kinase activity
  evidence_type: NAS
  original_reference_id: PMID:11016445
  review:
    summary: &gt;-
      Another annotation to the core MF term with NAS evidence. Redundant with IDA
      annotations but consistent.
    action: ACCEPT
references:
- id: GO_REF:0000033
  title: Annotation inferences using phylogenetic trees
- id: GO_REF:0000043
  title: Gene Ontology annotation based on UniProtKB/Swiss-Prot keyword mapping
- id: GO_REF:0000052
  title: Gene Ontology annotation based on curation of immunofluorescence data
- id: GO_REF:0000120
  title: Combined Automated Annotation using Multiple IEA Methods
- id: Reactome:R-HSA-163841
  title: Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation
  findings:
  - statement: This pathway covers irreversible post-translational modifications including
      gamma-carboxylation, hypusinylation, and hydroxylation - FN3K&#39;s deglycation activity
      does not fit this category of irreversible modifications.
    supporting_text: &gt;-
      After translation, many newly formed proteins undergo further covalent modifications
      that alter their functional properties and that are essentially irreversible under
      physiological conditions in the body. These modifications include the vitamin K-dependent
      attachment of carboxyl groups to glutamate residues and the conversion of a lysine
      residue in eIF5A to hypusine
- id: Reactome:R-HSA-6788867
  title: FN3K phosphorylates ketosamines
  findings:
  - statement: FN3K phosphorylates ketosamines on the third carbon of the sugar moiety,
      creating unstable intermediates that decompose (deglycation).
    supporting_text: &gt;-
      Ketosamine-3-kinase (FN3K) and ketosamine-3-kinase-related protein (FN3KRP) can
      phosphorylate protein-bound or free ketosamines on the third carbon of the sugar
      moiety and the resultant, unstable ketosamine 3-phosphates decompose under
      physiological conditions (a process called deglycation).
  - statement: FN3K and FN3KRP both phosphorylate psicosamines and ribulosamines, but only
      FN3K can phosphorylate fructosamines.
    supporting_text: &gt;-
      Both enzymes can 3-phosphorylate psicosamines (PsiAm) and ribulosamines (RibAm),
      but only FN3K can 3-phosphorylate fructosamines (FruAm) as well
- id: PMID:11016445
  title: Identification, cloning, and heterologous expression of a mammalian fructosamine-3-kinase.
  findings:
  - statement: Discovery paper identifying and cloning FN3K from erythrocytes, purified as
      35,000 Mr protein.
    supporting_text: &gt;-
      The enzyme responsible for this conversion was purified approximately 2,500-fold
      by chromatography on Blue Sepharose, Q Sepharose, and Sephacryl S-200 and shown
      to copurify with a 35,000-M(r) protein.
  - statement: Enzyme phosphorylates DMF, fructoselysine, fructoseglycine, and fructose in
      order of decreasing affinity.
    supporting_text: &gt;-
      They were shown to catalyze the phosphorylation of DMF, fructoselysine, fructoseglycine,
      and fructose in order of decreasing affinity.
  - statement: NMR analysis showed phosphate bound to third carbon of 1-deoxyfructose moiety.
    supporting_text: &gt;-
      Nuclear magnetic resonance analysis of phosphorylated DMF and phosphorylated
      fructoseglycine showed that the phosphate was bound to the third carbon of the
      1-deoxyfructose moiety.
  - statement: Phosphorylated glycated lysozyme but not unmodified lysozyme.
    supporting_text: They also phosphorylated glycated lysozyme, though not unmodified lysozyme.
  - statement: Proposed function is to initiate deglycation of fructoselysine and glycated proteins.
    supporting_text: &gt;-
      The physiological function of fructosamine-3-kinase may be to initiate a process
      leading to the deglycation of fructoselysine and of glycated proteins.
- id: PMID:11522682
  title: &#39;Human fructosamine-3-kinase: purification, sequencing, substrate specificity,
    and evidence of activity in vivo.&#39;
  findings:
  - statement: Characterized human FN3K as a 35-kDa monomer expressed in all mammalian tissues.
    supporting_text: &gt;-
      The protein thus identified is a 35-kDa monomer that appears to be expressed
      in all mammalian tissues.
  - statement: FL3P phosphorylation destabilizes FL adduct and leads to spontaneous decomposition,
      reversing nonenzymatic glycation.
    supporting_text: &gt;-
      This phosphorylation destabilizes the FL adduct and leads to its spontaneous
      decomposition, thereby reversing the nonenzymatic glycation process at an early stage.
  - statement: High affinity of FN3K for FL and wide distribution suggest function is deglycation
      of nonenzymatically glycated proteins.
    supporting_text: &gt;-
      The lability of FL3P, the high affinity of FN3K for FL, and the wide distribution
      of FN3K suggest that the function of this enzyme is deglycation of nonenzymatically
      glycated proteins.
  - statement: Deglycation system mediated by FN3K may protect cells from deleterious effects
      of nonenzymatic glycation.
    supporting_text: &gt;-
      a deglycation system mediated by FN3K may be an important factor in protecting
      cells from the deleterious effects of nonenzymatic glycation.
- id: PMID:11975663
  title: Fructosamine 3-kinase is involved in an intracellular deglycation pathway in
    human erythrocytes.
  findings:
  - statement: In vivo evidence of FN3K activity in erythrocytes with formation of phosphorylated
      hemoglobin intermediate.
    supporting_text: &gt;-
      incubation of human erythrocytes with 200 mM glucose not only caused the progressive
      formation of glycated haemoglobin, but also increased the level of an anionic form
      of haemoglobin containing alkali-labile phosphate, to approx. 5% of total haemoglobin.
  - statement: DMF (FN3K inhibitor) doubled accumulation of glycated hemoglobin but decreased
      phosphorylated form - proving FN3K involvement.
    supporting_text: &gt;-
      1-Deoxy-1-morpholinofructose (DMF), a substrate and competitive inhibitor of
      fructosamine 3-kinase, doubled the rate of accumulation of glycated haemoglobin,
      but markedly decreased the amount of haemoglobin containing alkali-labile phosphate.
  - statement: Removal of DMF caused decrease in glycated hemoglobin and transient increase in
      FN3P-Hb, demonstrating active deglycation cycle.
    supporting_text: &gt;-
      Returning erythrocytes incubated with 200 mM glucose and DMF to a low-glucose medium
      devoid of DMF caused a decrease in the amount of glycated haemoglobin, a transient
      increase in FN3P-Hb and a net decrease in the sum (glycated haemoglobin+FN3P-Hb).
  - statement: Second step is spontaneous decomposition of fructosamine 3-phosphate to free amine,
      3-deoxyglucosone, and Pi.
    supporting_text: &gt;-
      The second step of this &#39;deglycation&#39; process is most likely a spontaneous decomposition
      of the fructosamine 3-phosphate residues to a free amine, 3-deoxyglucosone and P(i).
- id: PMID:21492153
  title: Analysis of proteomic changes induced upon cellular differentiation of the
    human intestinal cell line Caco-2.
  findings:
  - statement: High-throughput proteomics study comparing proliferating and differentiated Caco-2 cells.
    supporting_text: &gt;-
      The proteome of proliferating Caco-2 cells was compared with that of fully
      differentiated cells.
  - statement: Two-dimensional gel analysis identified 53 differentially regulated proteins during
      differentiation.
    supporting_text: &gt;-
      Two-dimensional gel analysis yielded 53 proteins that were differently regulated
      during the differentiation process.
  - statement: Study provides expression correlation data but no mechanistic link to differentiation.
    supporting_text: &gt;-
      Thus, the proteomic approach in combination with a literature-based pathway analysis
      yielded valuable information about the differentiation process of Caco-2 cells on
      the molecular level
  full_text_unavailable: true
- id: file:human/FN3K/FN3K-deep-research-perplexity.md
  title: Deep research on FN3K from Perplexity
  findings:
  - statement: FN3K exhibits highly specific substrate recognition with preference for fructose-lysine
      residues and 10-100x higher affinity for epsilon-lysine vs N-terminal modifications.
  - statement: Structural studies show bulky aromatic residues (His288, Trp219, Phe252, Tyr296)
      create the specialized substrate-binding pocket.
  - statement: FN3K activity is redox-regulated via P-loop cysteine C24 forming disulfide-linked
      dimers in oxidized state.
  - statement: Multi-compartmental localization to cytosol, mitochondria, and nucleus supported
      by multi-omics studies.
core_functions:
- molecular_function:
    id: GO:0102194
    label: protein-fructosamine 3-kinase activity
  description: &gt;-
    Catalyzes ATP-dependent phosphorylation of fructoselysine residues on glycated
    proteins at the 3-position of the fructose moiety, generating fructosamine
    3-phosphate as an unstable intermediate.
  supported_by:
  - reference_id: PMID:11016445
    supporting_text: &gt;-
      Nuclear magnetic resonance analysis of phosphorylated DMF and phosphorylated
      fructoseglycine showed that the phosphate was bound to the third carbon of the
      1-deoxyfructose moiety.
  - reference_id: PMID:11522682
    supporting_text: &gt;-
      This phosphorylation destabilizes the FL adduct and leads to its spontaneous
      decomposition, thereby reversing the nonenzymatic glycation process at an early stage.
  directly_involved_in:
  - id: GO:0036525
    label: protein deglycation
  locations:
  - id: GO:0005829
    label: cytosol
  substrates:
  - id: CHEBI:24103
    label: fructosamine
    description: Primary substrate; glucose-derived Amadori products on lysine residues
  - id: CHEBI:87177
    label: ribulosamine
    description: Secondary substrate; ribose-derived ketosamines (KM ~2.6 uM)
  - id: CHEBI:87176
    label: psicosamine
    description: Lower affinity substrate (KM ~140-160 uM); also phosphorylated by FN3KRP
</code></pre>
            </div>
        </details>
    </div>

    <!-- Pathway Visualization Link -->
    

    <style>
        /* Markdown Section Styles */
        .markdown-section {
            margin-bottom: 1rem;
            border: 1px solid #e0e0e0;
            border-radius: 8px;
            padding: 1rem;
            background-color: #f8f9fa;
        }

        .markdown-section summary {
            cursor: pointer;
            user-select: none;
        }

        .markdown-section summary h3 {
            margin: 0;
            color: #495057;
            font-size: 1.1rem;
        }

        .markdown-section summary:hover h3 {
            color: #007bff;
        }

        .markdown-section[open] {
            background-color: #fff;
        }

        .markdown-content {
            margin-top: 1rem;
            padding: 1rem;
            border-top: 1px solid #dee2e6;
        }

        /* Markdown content styling */
        .markdown-content h1 { font-size: 1.5rem; margin-top: 1.5rem; }
        .markdown-content h2 { font-size: 1.3rem; margin-top: 1.3rem; }
        .markdown-content h3 { font-size: 1.1rem; margin-top: 1.1rem; }
        .markdown-content h4 { font-size: 1rem; margin-top: 1rem; }

        .markdown-content pre {
            background-color: #f8f9fa;
            border: 1px solid #dee2e6;
            border-radius: 4px;
            padding: 1rem;
            overflow-x: auto;
        }

        .markdown-content code {
            background-color: #f8f9fa;
            padding: 0.2rem 0.4rem;
            border-radius: 3px;
            font-family: 'Courier New', Courier, monospace;
            font-size: 0.9rem;
        }

        .markdown-content pre code {
            background: none;
            padding: 0;
        }

        .markdown-content table {
            border-collapse: collapse;
            width: 100%;
            margin: 1rem 0;
        }

        .markdown-content table th,
        .markdown-content table td {
            border: 1px solid #dee2e6;
            padding: 0.5rem;
            text-align: left;
        }

        .markdown-content table th {
            background-color: #f8f9fa;
            font-weight: bold;
        }

        .markdown-content blockquote {
            border-left: 4px solid #007bff;
            padding-left: 1rem;
            margin-left: 0;
            color: #666;
        }

        /* YAML Preview Styles */
        .yaml-preview {
            margin-top: 2rem;
            border: 1px solid #e0e0e0;
            border-radius: 8px;
            padding: 1rem;
            background-color: #f8f9fa;
        }

        .yaml-preview summary {
            cursor: pointer;
            user-select: none;
        }

        .yaml-preview summary h2 {
            margin: 0;
            color: #495057;
            font-size: 1.3rem;
        }

        .yaml-preview summary:hover h2 {
            color: #007bff;
        }

        .yaml-preview[open] {
            background-color: #fff;
        }

        .yaml-content {
            margin-top: 1rem;
            background-color: #f8f9fa;
            border: 1px solid #dee2e6;
            border-radius: 4px;
            padding: 1rem;
            overflow-x: auto;
        }

        .yaml-content pre {
            margin: 0;
            font-family: 'Courier New', Courier, monospace;
            font-size: 0.9rem;
            line-height: 1.4;
        }

        .yaml-content code {
            color: #333;
            background: none;
            padding: 0;
        }

        /* Pathway Link Styles */
        .pathway-link {
            margin: 1rem 0;
        }

        .btn-link {
            display: inline-block;
            padding: 0.5rem 1rem;
            background-color: #007bff;
            color: white !important;
            text-decoration: none;
            border-radius: 4px;
            font-weight: 500;
            transition: background-color 0.2s;
        }

        .btn-link:hover {
            background-color: #0056b3;
            text-decoration: none;
        }

        /* Voting buttons */
        .vote-buttons {
            display: inline-block;
            margin-left: 0.5rem;
        }

        .vote-btn {
            background: none;
            border: 1px solid #dee2e6;
            border-radius: 4px;
            padding: 2px 6px;
            margin: 0 2px;
            cursor: pointer;
            font-size: 0.9rem;
            transition: all 0.2s;
            opacity: 0.6;
        }

        .vote-btn:hover {
            opacity: 1;
            transform: scale(1.1);
        }

        .vote-btn.voted {
            opacity: 1;
            border-color: #28a745;
            background-color: #d4edda;
        }

        .vote-btn.voted-down {
            border-color: #dc3545;
            background-color: #f8d7da;
        }
    </style>

    <script>
        // Add collapsible functionality
        document.querySelectorAll('.collapsible').forEach(element => {
            element.addEventListener('click', function() {
                this.classList.toggle('collapsed');
            });
        });

        // Voting functionality
        const VOTE_URL = 'https://script.google.com/macros/s/AKfycbwPKH7d3seuPNBtB0ugVjqGeTiByyOGD5vkqB_Ck6K8eOcPQYbJqBOuz6GFgXHKBNWK/exec';

        // Get or create session ID
        let sessionId = localStorage.getItem('review_session_id');
        if (!sessionId) {
            sessionId = 's' + Date.now() + '_' + Math.random().toString(36).substr(2, 9);
            localStorage.setItem('review_session_id', sessionId);
        }

        // Show previous votes on page load
        document.addEventListener('DOMContentLoaded', function() {
            document.querySelectorAll('.vote-buttons').forEach(container => {
                const key = `vote_${container.dataset.g}_${container.dataset.a}_${container.dataset.act}`;
                const previousVote = localStorage.getItem(key);
                if (previousVote) {
                    const btn = container.querySelector(`[data-v="${previousVote}"]`);
                    if (btn) btn.classList.add(previousVote === 'up' ? 'voted' : 'voted-down');
                }
            });
        });

        // Handle vote clicks - Simple image beacon approach
        document.addEventListener('click', function(e) {
            if (!e.target.classList.contains('vote-btn')) return;

            // Prevent the click from bubbling to parent elements (like summary)
            e.preventDefault();
            e.stopPropagation();

            const btn = e.target;
            const container = btn.closest('.vote-buttons');
            if (!container) return;

            const voteType = btn.dataset.v;

            // Check if already voted (locally)
            const key = `vote_${container.dataset.g}_${container.dataset.a}_${container.dataset.act}`;
            const previousVote = localStorage.getItem(key);

            if (previousVote === voteType) {
                // Same vote - do nothing
                btn.style.animation = 'shake 0.5s';
                setTimeout(() => btn.style.animation = '', 500);
                return;
            }

            // Build URL
            const params = new URLSearchParams({
                gene_id: container.dataset.g,
                annotation_id: container.dataset.a,
                ref_id: container.dataset.r || '',
                action: container.dataset.act,
                vote: voteType,
                session_id: sessionId,
                ua: navigator.userAgent.substring(0, 100)
            });

            // Clear previous vote styling
            container.querySelectorAll('.vote-btn').forEach(b => {
                b.classList.remove('voted', 'voted-down');
            });

            // Apply new vote styling immediately (optimistic UI)
            btn.classList.add(voteType === 'up' ? 'voted' : 'voted-down');

            // Store locally
            localStorage.setItem(key, voteType);

            // Send vote using fetch with no-cors mode (fire and forget)
            const fullUrl = VOTE_URL + '?' + params;
            console.log('Sending vote to:', fullUrl);

            // Use fetch in no-cors mode - we won't get a response but the request will be sent
            fetch(fullUrl, {
                mode: 'no-cors',
                method: 'GET'
            }).then(() => {
                console.log('Vote request sent (no response due to no-cors mode)');
            }).catch(err => {
                console.warn('Vote may not have been recorded, but saved locally:', err);

                // Fallback: try image beacon as well
                const img = new Image();
                img.src = fullUrl;
            });
        });

        // Optional: Add shake animation for feedback
        const style = document.createElement('style');
        style.textContent = `
            @keyframes shake {
                0%, 100% { transform: translateX(0); }
                25% { transform: translateX(-5px); }
                75% { transform: translateX(5px); }
            }
        `;
        document.head.appendChild(style);
    </script>
</body>
</html>